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ABSTRACT 
Aldehyde dehydrogenase 2 (ALDH2), one of 19 ALDH superfamily members, catalyzes the 
NAD+-dependent oxidation of aldehydes to their respective carboxylic acids. In this study, we 
further characterized the inhibition of four psoralen and coumarin derivatives towards ALDH2 
and compared them to the ALDH2 inhibitor daidzin for selectivity against five ALDH1/2 
isoenzymes. Compound 2 (Ki=19 nM) binds within the aldehyde-binding site of the free enzyme 
species of ALDH2. Thirty-three structural analogs were examined to develop a stronger SAR 
profile. Seven compounds maintained or improved upon the selectivity towards one of the five 
ALDH1/2 isoenzymes, including compound 36, a selective inhibitor for ALDH2 (Ki=2.4 µM) 
and compound 32, which was 10-fold selective for ALDH1A1 (Ki=1.2 µM) versus ALDH1A2. 
Further medicinal chemistry on the compounds’ basic scaffold could enhance the potency and 
selectivity for ALDH1A1 or ALDH2 and generate chemical probes to examine the unique and 
overlapping functions of the ALDH1/2 isoenzymes. 
INTRODUCTION 
Aldehydes can lead to cytotoxicity and carcinogenesis when present in large enough quantities 
within the human body.1, 2 The human body encounters numerous aldehydes from both the 
external environment and the internal metabolism of biomolecules.3 The aldehyde 
dehydrogenases (ALDHs) are one of many enzyme systems the body utilizes to alleviate 
aldehyde stress.4 The human genome has 19 functional genetic loci for members of the ALDH 
superfamily, the majority of which catalyze the NAD(P)+ dependent oxidation of aldehydes to 
their respective carboxylic acids or CoA esters.5, 6 ALDHs are separated into families and 
subfamilies based on their sequence similarity.7 The 19 ALDHs share similar yet distinct 
functions due to their varying substrate specificities and gene expression differences. Some are 
ubiquitously expressed, such as ALDH1A1 and ALDH2, while are other are expressed 
preferentially in certain tissues or during certain periods of development. Naturally occurring 
mutations within various ALDHs can cause human diseases such as Sjogren-Larsson syndrome 
(ALDH3A2),8 type II hyperprolinemia (ALDH4A1),9 4-hydroxybutyricaciduria (ALDH5A1)10 , 
and pyridoxine dependent epilepsy (ALDH7A1).11 
The ALDH1/2 family consists of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH2. 
The five isoenzymes primarily oxidize aliphatic aldehydes of varying length. ALDH1A1, 
ALDH1A2, and ALDH1A3 are cytosolic proteins which are involved in retinoid metabolism.12 
ALDH1A1 has been implicated in providing resistance to certain anti-cancer agents, such as 
cyclophosphamide, as well as having a functional role in cancer stem cells.13-15 ALDH1A2 and 
ALDH1A3 are critical for embryonic development in mice as individual genetic knockout of 
these two genes do not produce viable animals.16, 17 ALDH2 is a mitochondrial enzyme most 
known for its role in acetaldehyde metabolism during the conversion of ethanol to acetic acid.18 
Other isoenzymes such as ALDH1A1 and ALDH1B1 also can contribute to the oxidation of 
acetaldehyde, especially when ALDH2 activity is reduced by the presence of the ALDH2*2 
allele.19-21 ALDH1B1, a mitochondrial enzyme most similar to ALDH2, has recently been linked 
with colon cancer and diabetes.22, 23 ALDH1A1 and ALDH2 have also been linked to the 
metabolism of dopamine within different areas of the brain.24 For the ALDH1/2 family of 
isoenzymes it is difficult to make specific assignment of function due to their overlapping 
substrate specificities. The discovery and development of isoenzyme-selective inhibitors or 
activators would better allow investigators to identify the individual contribution of these 
individual isoenzymes to the metabolism of these common substrates.  
The majority of the ALDH superfamily, including the ALDH1/2 family, shares the same basic 
catalytic mechanism. NAD(P)+ binds to the enzyme and can sample multiple binding positions.25 
The conserved catalytic cysteine (Cys302 in ALDH2) is activated and performs a nucleophilic 
attack on the carbonyl carbon of the aldehyde forming a tetrahedral intermediate.26 Once 
NAD(P)+ occupies the necessary binding position, the aldehydic hydride ion is transferred to the 
nicotinamide ring of NAD(P)+ forming NAD(P)H. The substrate-enzyme complex then 
undergoes a conformation change in which the NAD(P)H moves away to allow access of the 
catalytic site to a water molecule. The water molecule is deprotonated by a conserved glutamate 
residue (Glu268 in ALDH2) and performs a nucleophilic attack on the carbonyl carbon of the 
acyl-enzyme intermediate.27 The bond between the sulfur and carbonyl carbon is then broken 
regenerating the free enzyme and producing the carboxylic acid end product. Due to the similar 
catalytic mechanisms for the ALDH1/2 family, mechanism-based inhibitors may lack selectivity. 
However, selectivity can be achieved through taking advantage of the different aldehyde binding 
sites of the ALDH family which have evolved over time through substitutions of residues in the 
substrate binding tunnel. 
One use of a chemical probe for ALDH2 is the treatment of alcohol abuse. The ALDH2*2 allele 
is found in ~40% of East Asians and leads to the alcohol flush response.28, 29 The E504K 
substitution (E487K after removal of the mitochondrial targeting signal) in the ALDH2*2 allele 
leads to decreased acetaldehyde metabolism to the point where individuals with the allele will 
develop nausea, vomiting, and vasodilation shortly after alcohol consumption. The ALDH2*2 
allele is associated with a lower risk of alcoholism due in part to this physiological response.30 
Mimicking the ALDH2*2 response is an established treatment option for alcohol abuse. 
Disulfiram and daidzin and their derivatives are commonly used to treat alcohol abuse as 
ALDH2 inhibitors.31 However, disulfiram is non-selective and also inhibits ALDH1A1 as 
disulfiram causes the irreversible inactivation of ALDH enzymes through carbamoylation of the 
catalytic cysteine residue.32, 33 Additionally, disulfiram metabolites will chelate with copper and 
thereby inhibit copper-dependent enzymes.34, 35 Though daidzin reversibly inhibits ALDH2 two 
orders of magnitude greater than ALDH1A1, its effect on the activity of ALDH1A2, ALDH1A3, 
and ALDH1B1 has been understudied.36, 37 
We sought to further characterize the original set of psoralen and coumarin derivatives 
discovered in a high-throughput screen and expand upon those hits by examining a series of 
related analogs as inhibitors of the ALDH1/2 isoenzymes. These compounds are unique from the 
covalent inactivating Aldi compounds and N-N-diethylaminobenzaldehyde that we and others 
have previously characterized.38-40 Our initial goal was to determine the compounds’ mechanism 
of action and to understand the structural basis for their inhibition of ALDH2, as their inhibition 
towards ALDH2 was the strongest amongst the ALDH1/2 isoenzymes. In order to create a 
common basis for comparison in our assays the inhibition profile for daidzin toward these same 
ALDH1/2 family members was also determined. Thirty-three additional psoralen and coumarin 
analogs were then evaluated as inhibitors toward the ALDH1/2 family of isoenzymes. Although 
many of the structural variations resulted in the loss of inhibition towards ALDH2, one coumarin 
derivative was found to be an ALDH2-selective inhibitor. Surprisingly a different coumarin 
derivative was found to be an ALDH1A1-selective inhibitor. Both compounds could be further 
developed to make them more selective for their respective isoenzymes. The overall chemical 
similarity between the compounds while possessing different isozyme selectivity highlights the 
effect small chemical changes can have when developing isoenzyme-selective probes for ALDH 
isoenzymes. 
RESULTS AND DISCUSSION 
Further Characterization of the Four Initial Aromatic Lactones 
Four aromatic lactones were previously identified as inhibitors of the ALDH1/2 family of 
enzymes, 1 (2CB5), 2 (2P3), 3 (2P4) and 4 (2BS4) (Figure 1).41 The IC50 values for daidzin for 
the ALDH1/2 family were measured to compare our results to compounds (including CVT-
10216) already described in the literature as ALDH2-selective inhibitors.36, 37, 42  Consistent with 
prior work, daidzin was found to be about 100-fold more potent toward ALDH2 than ALDH1A1 
(Table 1). However, our IC50 values are 10-fold higher than prior values. The discrepancy 
between the values reported here and the values in the literature stems from the fact that our 
group uses propionaldehyde (Km for ALDH2 is ~0.1 µM) as the standard substrate for the 
ALDH1/2 isoenzymes at 100 µM and the original reports on isoflavones, such as daidzin and 
prunetin, utilized formaldehyde ((Km for ALDH2 is ~320 µM)43 as the substrate at 600 µM.36  
We chose to utilize propionaldehyde, rather than formaldehyde, as substrate in our assays in 
order to have as many enzymes as possible evaluated for inhibition against a single common 
substrate (propionaldehyde was used in all enzyme assays, except ALDH3A1).  On the other 
hand, because IC50 measurements are dependent on the concentration utilized in the assays 
relative to their isoenzyme specific Km values, our assays will be more stringent for inhibition, 
because only very strong inhibitors will be able to overcome the 1,000-fold concentration excess 
of propionaldehyde in the ALDH2 assay. In regards to the other ALDH1/2 enzymes, we found 
daidzin to inhibit ALDH1B1 (IC50 = 5.1 ± 0.5 µM) and ALDH1A2 (IC50 = 4.5 ± 0.6 µM) with 
similar potencies to ALDH2 (IC50 = 3.5 ± 0.1 µM), while being less potent toward ALDH1A1 
and ALDH1A3. Inhibition of ALDH1A1 and ALDH1A3 by daidzin was observed, but 
compound solubility issues prevented full dose-response analyses.  
Compounds 1, 2, and 3 are psoralen derivatives with varying alkyl substitutions to the aromatic 
ring structure (Figure 1). Compound 4 is a coumarin derivative with a methyl 2-
methoxypropanoate chain and is a potential substrate for the in vitro esterase reaction of 
ALDH2. The IC50 values of the four aromatic lactones for seven isoenzymes were determined in 
order to better characterize the selectivity of the compounds towards/for the ALDH1/2 family of 
isoenzymes versus other ALDH isoenzymes as previously only single point activity 
measurements had been utilized. 
 
Figure 1 Structures of the four partially characterized aromatic lactones. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 IC50 values were determined for 1, 2, 3, 4, and daidzin with nine ALDH isoenzymes. 
Values are the mean/SEM of three independent experiments (n=3) 
  IC50 (µM)                               
 Inhibitor ALDH2 ALDH1B1 ALDH1A1  ALDH1A2 ALDH1A3 ALDH1L1 (rat) ALDH3A1 
Daidzin 3.5 ± 0.1 5.1 ± 0.5 >200 4.5 ± 0.6 >200 NI NI 
1 0.34 ± 0.05 
0.88 ± 
0.28 
0.34 ± 
0.05# 0.76 ± 0.07 1.1 ± 0.1 NI NI 
2 0.11 ± 0.02 
0.36 ± 
0.12 
0.22 ± 
0.05 0.30 ± 0.04 
0.40 ± 
0.06 NI NI 
3 0.19 ± 0.01 
0.31 ± 
0.07# NI 
0.33 ± 
0.04# 
0.27 ± 
0.05 NI NI 
4 1.5 ± 0.3 NI NI NI NI NI NI 
#~60% max inhibition  NI= no inhibition 
 
The four lactones lacked inhibitory effect toward ALDH1L1 (rat), ALDH3A1, ALDH4A1 and 
ALDH5A1.41 4 showed selectivity towards ALDH2 versus the other eight isoenzymes tested 
with an IC50 value of 1.5 ± 0.3 µM. The other three compounds inhibited ALDH2 most strongly, 
though they also inhibited the majority of the other ALDH1/2 isoenzymes at sub-micromolar 
concentrations. The lowest IC50 measured was that of 2 for ALDH2 (IC50 = 0.11 ± 0.02 µM). 2 
inhibited each of the five ALDH1/2 isoenzymes the strongest and was the only one of the three 
which completely inhibited all five isoenzymes. 3 has similar IC50 values as 2 for ALDH2 (IC50 
= 0.19 ± 0.01 µM) and ALDH1A3, but only partially inhibits ALDH1B1 and ALDH1A2 and 
does not inhibit ALDH1A1. 1 had the highest IC50 values of the aromatic lactones for the five 
ALDH1/2 isoenzymes and only partially inhibited ALDH1A1. The partial inhibition of the 
enzymes by these compounds could not be determined from the single point activity 
measurements previously reported.41 The number and length of the alkyl substituents on the 
aromatic lactones positively correlates with the potency of inhibition towards ALDH1A1 
(Figure 1 and Table 1).  Covariation experiments were completed with 2, 3, and 4 to better 
understand their mechanism of inhibition toward ALDH2 (Figure 2A-C). 2, 3, and 4 were all 
found to be competitive versus varied NAD+ for ALDH2, with Ki values of 19 ± 1 nM, 87 ± 8 
nM and 310 ± 36 nM respectively. In prior work, 3 was found to be non-competitive (mixed-
type) with respect to varied propionaldehyde for ALDH2 with a Ki = 35 nM.41 These 
mechanisms of inhibition were surprising, since the esterase screen utilized to discover these 
compounds was designed to select against compounds competitive toward coenzyme binding.44 
Therefore, we solved the crystal structure of 2 bound to ALDH2. Compound 2 was chosen for 
this analysis, as it is the largest of the three psoralen derivatives, fully inhibited all ALDH1/2 
isoenzymes, and had the lowest Ki value. The structure of ALDH2 in complex with compound 2 
was solved to a resolution of 2.40Å, with the ligand modeled at full occupancy in each of the 
eight monomers (Table 2). In the absence of coenzyme, 2 binds within the substrate binding site 
of ALDH2 (Figure 2D) and is surrounded by four phenylalanine side chains (residues 170, 296, 
459, and 465). To accommodate the binding of 2, the catalytic Cys302 rotates towards the NAD+ 
binding site. The propyl alkyl substituent extends into a pocket formed in part by Glu268, 
Glu476, Trp177, and Thr244 while the methyl substituents on the furan ring are oriented towards 
the solvent exposed entrance. Given the larger binding site of ALDH1A1, it is possible the 
additional contacts provided by the extension of the propyl chain into this pocket are essential for 
ALDH1A1 inhibition. The narrower binding sites for the other ALDH1/2 members apparently 
do not require these contacts. The lactone carbonyl of 2 mimics the position of a potential 
aldehyde substrate and hydrogen bonds with the peptide nitrogen of Cys302 (Figure 2E) in a 
manner similar to that predicted for the incoming aldehyde substrate as it engages the oxyanion 
hole. In addition to the contribution from hydrophobic interactions, this one hydrogen bond 
orients the compound in the substrate binding site.  
 
 
Figure 2 – The binding characteristics of substituted psoralens to ALDH2. Lineweaver-Burk 
representations for the competitive inhibition patterns of compounds 2 (A), 3 (B), and 4 (C) 
versus varied NAD+ at saturating concentrations of propionaldehyde (1 mM). The reported Ki 
values are the mean/SEM of at least three independent experiments (n≥3). (D) Representative 
electron density map for 2 bound to ALDH2 with the original figure-of-merit weighted Fo-Fc 
map in green contoured at 2.5 standard deviations and the original figure-of-merit weighted 2Fo-
Fc map in blue contoured at 1.0 standard deviations obtained after initial refinement before 
addition of solvent or ligand to the structure factor calculations. (E) Hydrogen bond between 
lactone carbonyl of 2 and peptide nitrogen of Cys302 shown as black dashed line. (F) 2 binds 
within the catalytic tunnel of ALDH2. The structure of ALDH2 is displayed using a ribbons and 
side chain representation with the molecular surface of the substrate binding site displayed in 
transparent green. The orientation of 2 in this panel is chosen to match the orientation of the 
compounds in Table 3 to better visualize the SAR. 
 
 
 
 
 
 
 
 
 
 
Table 2 Data collection and refinement statistics for enzyme-compound complexes 
Compound 2 15 34 32 
Enzyme ALDH2 ALDH1A1 ALDH1A1 ALDH1A1 
PDB Code 5L13 5L2M 5L2N 5L2O 
Data Collection     
Date of Collection Nov 2012 Mar 2016 Mar 2016 Mar 2016 
Space Group P212121 P422 P422 P1 
Cell Dimensions     
a,b,c (Å) 99,127,295 109,109,83 109,109,83 91,98,127 
α,β,γ (deg) 90,90,90 90,90,90 90,90,90 81,86,64 
Resolution (Å) 50.0-2.40 50.0-1.70 50.0-1.70 50.0-2.05 
Rmerge 0.093 (0.280)a 0.077 (0.501) 0.099 (0.654) 0.069 (0.280) 
Rmeas NDb 0.083 (0.546) 0.108 (0.716) 0.093 (0.377) 
Rpim NDb 0.032 (0.214) 0.041 (0.284) 0.061 (0.251) 
CC1/2 NDb 0.943 (0.778) 0.905 (0.637) 0.955 (0.845) 
I/σ<I> 16.2 (5.0) 19.3 (3.6) 14.2 (2.8) 10.7 (2.7) 
Completeness (%) 94.2 (85.7) 97.6 (97.0) 98.9 (100) 90.8 (91.7) 
Redundancy 5.0 (4.8) 6.4 (6.3) 6.4 (6.1) 2.1 (2.1) 
Refinement 
    No. of reflections 131537 51675 52057 211433 
No. of protein atoms 30485 3811 3798 30488 
No. of water molecules 1711 309 283 2326 
No. of inhibitor molecules 8 1 1 8 
Occupancy of inhibitor(s) 1 1 1 1 
Rwork/Rfree 0.16/0.21 0.22/0.24 0.21/0.24 0.17/0.20 
RMSD     
Bond Length (Å) 0.009 0.010 0.010 0.012 
Bond Angle (deg) 1.324 1.395 1.373 1.388 
Ramachandran plotc 
    Preferred (%) 96.05% 97.14% 97.34% 97.05% 
Outliers (%) 0.56% 0.20% 0.20% 0.20% 
Clashscore (percentile)c 1.69 (100%) 2.76 (99%) 1.98 (99%) 1.70 (100%) 
MolProbity score (percentile)c 1.16 (100%) 1.22 (98%) 1.09 (99%) 1.23 (100%) 
Average B (Å) 
    Protein 27.5 38.3 40.5 19.5 
Inhibitor 
Chain A: 26.4 
B: 33.4 C: 29.2 
D: 27.2 E: 28.0 
F: 39.2 G: 34.2 
H: 28.3 
29.7 38.0 
Chain A: 28.8  
B: 30.3 C: 24.8 
D: 23.9 E: 33.9 
F: 31.0 G: 26.3 
H: 33.9 
Solvent  29.4 30.2 35.1 26.5 
         
aValues in parenthesis are those from the highest resolution shell. 
NDb Processing values not available in HKL2000 version 0.96 
cGenerated with Molprobity. 
 
Figure 3 – Potential interactions between psoralens and the active site of ALDH2. (A) 
Overlay of 2 (black) bound to ALDH2 (orange) and NAD+/NADH (purple/green) bound to 
ALDH2 (cyan). (B) Expanded view of the same overlay showing surface of ALDH2 for each 
binding partner using the same color scheme as in panel A. (PDB ID codes 1O00, 1O02, 1O04) 
 
 
The shift of Cys302 towards the NAD+ site likely explains the competitive inhibition pattern 
towards varied NAD+, since both NAD+ and 2 bind to the same enzyme species in solution - the 
free enzyme. A structural comparison of 2 and productive NAD(H) binding to ALDH2 
demonstrates the impact of Cys302 movement on coenzyme binding (Figure 3). When Cys302 
resides in this shifted position, NAD+ cannot be productively positioned to accept the hydride ion 
during the dehydrogenase reaction. Additionally the propyl chain proximal to the aromatic 
lactone may also hinder the positioning of the nicotinamide ring of NAD+. Similarly, 2 cannot 
bind to the free enzyme form of ALDH2 if Cys302 is not rotated away. Consequently, the 
binding of 2 prevents the productive binding of NAD+ and vice versa. Although the majority of 2 
binds within the substrate binding site, just enough of the compound overlaps with the 
nicotinamide binding pocket to explain the competitive inhibition pattern toward NAD+. 
Compound 2 prevents the productive positioning of NAD+ within the enzyme for catalysis. 
However, the binding of NAD+ in a manner not conducive to catalysis is still possible in the 
presence of 2. This is further supported by the inhibition of ALDH2 by 2 under saturating NAD+ 
conditions for the covariation experiment with propionaldehyde.41 The non-competitive (mixed-
type) inhibition pattern towards substrate could also be explained by non-productive binding of 
NAD+ to the enzyme in the presence of inhibitor.  For most linear aliphatic substrates ALDH2 
appears to follow an iso-ordered bi-bi reaction mechanism where NAD+ will bind to the enzyme 
first and the coenzyme undergoes conformational changes prior to assuming the productive 
conformation required for hydride transfer.45, 46 When propionaldehyde is varied under saturating 
NAD+ concentrations, the binding of NAD+ to the free enzyme would be essentially irreversible 
and reduce the population of free enzyme in solution to essentially zero. However, 2 may still 
bind to one of the non-productively positioned complexes with NAD+, such off-pathway 
complexes would be consistent with the observed kinetic data.47, 48   
As previously discussed,41 4 may inhibit ALDH2 through multiple mechanisms, including both 
through positioning of the aromatic lactone moiety near Cys302, but also through its ester group 
as a potential competitive esterase substrate. Using the structure of 2 bound to ALDH2 as a basis 
for interpretation, either the aromatic lactone or the ester could face Cys302 when binding in the 
substrate binding pocket. Additional experiments demonstrate that 4 exhibits a time-dependence 
for inhibition, but the time-dependence is not observed for the inhibition phase, but is related to 
the length of time the enzyme remains inhibited after complex formation. After more than a day 
of incubation with stoichiometric amounts of 4 and ALDH2 the amount of inhibition begins to 
decrease, suggesting a slow hydrolysis of the ester over time. However, we have not been able to 
determine the contribution of ALDH2 to ester hydrolysis versus the natural non-enzymatic 
hydrolysis of the ester in solution, since they have similar time-frames and the free acid form of 
4 is not inhibitory (see below). Clearly though, the hydrolysis of 4 limits its use as an ALDH2 
inhibitor for in vivo studies. 
Initial Characterization of Psoralen- and Coumarin-Derived Analogs 
High-throughput screening assays are fraught with complications in which the initial hit 
compounds promote protein aggregation or interfere with the screening assay in a manner that 
resembles inhibition.  Consequently, utilization of an orthogonal assay system where the 
analytical readout is distinct and the development of interpretable SAR on the hits help to guard 
against pursuing non-specific compounds. We purchased other psoralen- and coumarin-derived 
analogs to develop SAR on the initial coumarin and psoralen compounds, and to understand the 
selectivity of the psoralen analogs for ALDH2 so we could take advantage of the selectivity of 4 
toward ALDH2. Because of the behavior of 4, we hypothesized that similar compounds, without 
the ester group, could reversibly inhibit ALDH2 while maintaining selectivity. A total of 33 
compounds were ordered from ChemDiv, ChemBridge, and Sigma-Aldrich as representatives of 
all the available analogs using the binding location of 2 to ALDH2 as a guide for compound 
selection. Twelve compounds share the psoralen sub-structure of 1, 2, and 3 and twenty-one 
compounds share the coumarin sub-structure of 4. The effect of 10 µM compound on the activity 
of ALDH1A1, ALDH2, and ALDH3A1 was measured to determine selectivity amongst these 
three isoenzymes (Tables 3 and 4). The compound scaffold is oriented as seen in Figure 2F. 
 
 
 
 
 
Table 3 Structure activity relationships for psoralen derivatives based on percent activity at 10 
µM compound. The values for 1, 2, and 3 from our previous study are included for comparison. 
Compounds picked for further study highlighted in gray.  Values are the mean/SEM from at least 
three trials (n≥3). 
O OO
R1
R2
R3 R4 R5
R6
 
                % Activity @ 10µM Compound 
Compound R1 R2 R3 R4 R5 R6 LogP ALDH1A1 ALDH2 ALDH3A1 
1 H H CH3 H CH3 propyl 4.47 48.6 ± 2.3 6.25 ± 0.49 96.1 ± 8.3 
2 H CH3 CH3 H CH3 propyl 4.92 36.3 ± 3.2 1.61 ± 0.14 86.3 ± 4.2 
3 H CH3 CH3 H CH3 CH3 4.39 90.5 ± 4.0 19.5 ± 1.2 95.3 ± 6.4 
5 H H t-Bu H CH3 CH3 3.94 94.5 ± 0.1 69.7 ± 2.3 87.0 ± 1.3 
6 CH3 CH3 CH3 H CH3 CH3 4.36 78.4 ± 1.9 87.2 ± 0.4 102 ± 4 
7 H CH3 CH3 H propyl H 4.47 74.1 ± 2.0 23.8 ± 1.4 80.4 ± 1.4 
8 H 
  
H CH3 CH3 4.48 64.3 ± 2.7 61.3 ± 1.6 96.1 ± 2.8 
9 H CH3 CH3 H 
  
3.89 82.4 ± 0.8 42.2 ± 0.5 93.4 ± 3.5 
10 H CH3 CH3 H 
  
4.27 56.3 ± 2.7 16.3 ± 1.1 94.1 ± 2.1 
11 H CH3 CH3 H 
  
4.26 50.8 ± 2.3 8.25 ± 0.51 87.1 ± 4.9 
12 H H CH3 H CH3 benzyl 4.98 58.5 ± 2.9 83.6 ± 1.0 90.3 ± 5.1 
13 H H phenyl H CH3 CH3 4.80 87.4 ± 4.4 92.8 ± 2.7 88.9 ± 4.1 
14 H CH3 CH3 H benzyl H 4.80 57.0 ± 1.3 73.7 ± 1.6 81.6 ± 2.8 
15 H CH3 CH3 H CH3 N
O   
4.06 8.69 ± 0.42 3.80 ± 1.32 105 ± 2 
16 H CH3 CH3 H CH3 HN
O  
4.52 93.6 ± 6.5 69.8 ± 4.0 68.3 ± 10.2 
Table 4 Structure activity relationships for coumarin derivatives based on percent activity at 10 
µM compound. The values for 4 from our previous study are included for comparison. 
Compounds picked for further study highlighted in gray. Values are the mean/SEM from at least 
three trials (n≥3). 
OO
R1
R4 R5
R6
R2
R3
 
                % Activity @ 10µM Compound 
Compound R1 R2 R3 R4 R5 R6 LogP ALDH1A1 ALDH2 ALDH3A1 
4 H 
 
O
O
O
 
H H CH3 H 1.90 84.8 ± 1.8 5.72 ± 1.18 94.5 ± 8.4 
17 H O
O
  
H H CH3 H 1.72 68.7 ± 2.3 94.4 ± 0.2 101 ± 2 
18 H 
 
O
O
 
H H CH3 H 1.37 52.2 ± 2.4 99.1 ± 2.8 64.1 ± 3.9 
19 H 
O
O
  
H H H H 1.40 91.4 ± 3.4 93.3 ± 1.2 106 ± 2 
20 H O
O
H2N   
H H CH3 H 1.71 28.5 ± 0.6 89.5 ± 2.8 67.1 ± 1.9 
21 H 
O
  
H H CH3 H 2.46 80.2 ± 5.1 94.8 ± 3.7 36.4 ± 0.8 
22 H 
 
O
O
HO
 
H H CH3 H 1.63 97.5 ± 0.9 99.3 ± 2.1 93.9 ± 5.6 
 
Table 4, Continued Structure activity relationships for coumarin derivatives based on percent 
activity at 10 µM compound. The values for 4 from our previous study are included for 
comparison. Compounds picked for further study highlighted in gray.  Values are the mean/SEM 
from at least three trials (n≥3). 
OO
R1
R4 R5
R6
R2
R3
 
                % Activity @ 10µM Compound 
Compound R1 R2 R3 R4 R5 R6 LogP ALDH1A1 ALDH2 ALDH3A1 
23 H CH3 
 O  
CH3 CH3 3.92 71.5 ± 2.1 46.4 ± 1.7 98.1 ± 1.3 
24 O  
H H H H 1.77 61.0 ± 0.4 95.2 ± 0.1 28.3 ± 0.9 
25 CH3 
 
O
O  
H CH3 CH3 2.10 67.4 ± 1.3 80.2 ± 3.0 79.2 ± 2.1 
26 H 
OO
 
H CH3 H 2.11 65.2 ± 1.8 25.5 ± 4.2 53.6 ± 1.6 
27 H O  H H CH3 H 3.01 35.5 ± 0.8 
94.6 ± 
2.6 9.46 ± 0.87 
28 H 
O
 
H H CH3 H 3.94 37.3 ± 0.4 93.3 ± 1.4 23.7 ± 1.0 
29 H 
O
O
  
H H CH3 H 3.19 29.0 ± 1.4 97.8 ± 0.9 67.1 ± 6.1 
30 H  
O
N  H H CH3 H 1.22 35.7 ± 0.7 
41.3 ± 
2.5 20.4 ± 2.1 
31 H 
N
H
O
O
 
H H CH3 H 2.85 49.6 ± 3.0 95.0 ± 0.2 95.5 ± 2.4 
32 H 
 
N
 
H H CH3 H 3.63 14.3 ± 2.1 71.7 ± 1.1 109 ± 2 
33 H 
 
O
O
 
H H 
 
2.64 58.7 ± 1.2 64.4 ± 1.2 103 ± 1 
34 H S
O
O
O   
H H CH3 benzyl 3.44 24.6 ± 3.8 99.7 ± 1.2 86.9 ± 4.3 
35 H OH H H CH3 
O
OH
 
1.82 96.6 ± 4.0 101 ± 1 105 ± 3 
36 H H Br H H 
N
OH
 
2.10 96.0 ± 4.0 48.2 ± 2.0 91.7 ± 2.8 
37 H CH3 
 
O NH
 
H CH3 H 2.05 59.8 ± 3.1 96.3 ± 1.9 105 ± 3 
 
The first three analogs (5-7) had additional alkyl chains added to the psoralen structure. The 
addition of a t-butyl group at R3 in 5 lowered the inhibition towards ALDH2. The addition of a 
methyl group to R1 in 6 nearly eliminated inhibition towards ALDH2. Lengthening the alkyl 
chain at R5 to three carbons in 7 maintained inhibition towards ALDH2. Increasing the size of 
the ring structure of psoralen had differing results. The addition of a cyclohexane to the furan 
ring in 8 lessened inhibition towards ALDH2. Additional rings proximal to the lactone carbonyl 
(9-11) maintained inhibition towards ALDH2 showing some selectivity against ALDH1A1. The 
addition of a phenyl group at R3 in 13 eliminated inhibition towards ALDH1A1 and ALDH2. 
The addition of a benzyl group at either R5 in 14 or R6 in 12 negatively impacted inhibition of 
ALDH2, but led to moderate inhibition of ALDH1A1.  Compounds 15 and 16 represent a large 
group of available compounds in which psoralen derivatives are linked to other chemical 
structures through a 1-(piperidin-1-yl)propan-1-one (15) or N-benzylpropionamide (16) linker at 
R6. The 1-(piperidin-1-yl)propan-1-one linker is tolerated, as 15 inhibits both ALDH1A1 and 
ALDH2 >90% at 10µM. Compound 16 was the only psoralen analog which showed inhibition 
towards ALDH3A1, suggesting the N-benzylpropionamide linker itself is responsible for the 
ALDH3A1 inhibition. 
Additions to the psoralen scaffold generally resulted in the loss of inhibition towards ALDH2 
due to the narrow substrate binding site of ALDH2 (Figure 2F). Adding bulky side chains to the 
aromatic ring structure reduced or eliminated inhibition of ALDH2 and eventually other 
ALDH1/2 isoenzymes as seen with the aromatic side chains in 12-14 and the t-Bu group in 5. 
Even smaller groups such as the methyl added to the central aromatic ring in 6 can lead to loss of 
inhibition. Even though increasing the size of the psoralen derivatives increases the chances of 
eliminating ALDH2 inhibition, the addition of a fourth ring proximal to the lactone (9-11) 
maintained ALDH2 selectivity versus ALDH1A1.  
The coumarin analogs are variations of 4 which all lack the ester group of 4. As reported 
previously, slightly changing the ester portion of 4 led to the elimination of ALDH2 inhibition.41 
Three different methyl ketones (17-19) similar to 4 did not inhibit ALDH2. Additionally 17 and 
18 inhibited ALDH1A1 and/or ALDH3A1 unlike 4. An amide (20) similar to 4 inhibited 
ALDH1A1 as well. Removing the ester side chain to leave the ether (21) led to inhibition of 
ALDH3A1, while 22, the free acid form of 4, did not inhibit any ALDH isoenzymes. These 
results are consistent with 4 behaving differently than the other described analogs and the fact 
that carboxylates generally are poor inhibitors of ALDH1/2 isoenzymes.  
As subtle changes to the methyl 2-methoxypropanoate group of 4 at position R2 led to the 
elimination of ALDH2 inhibition and the loss of selectivity against ALDH1A1 and ALDH3A1, 
more diverse substituents were examined. The addition of oxygen-containing rings had varied 
results.  A 3-methylfuran ring at R3 and R4 in 23 led to partial inhibition of ALDH2, while 
addition of a furan ring at R1 and R2 in 24 led to strong inhibition of ALDH3A1 with no 
inhibition of ALDH2. The addition of 4H-pyran-4-one at R2 and R3 in 25 led to slight inhibition 
of ALDH1A1. The addition of a δ-valerolactone at R2 and R3 in 26 led to inhibition of ALDH2 
with lesser inhibition of ALDH1A1 and ALDH3A1. Compounds 27-33 changed the methyl 2-
methoxypropanoate group at R2 in 4 to more diverse structural groups. In most of these 
compounds changes at R2 increased inhibition towards ALDH1A1 and ALDH3A1, but 
diminished inhibition of ALDH2. Compounds 27 and 28 contain unsaturated alkyl chains at R2 
and inhibit ALDH1A1 and ALDH3A1. Compound 29 has a large 2-oxo-2-phenylethoxy group at 
R2 and inhibits ALDH1A1, as well as demonstrating moderate inhibition of ALDH3A1. 
Compound 30 has a terminal nitrile at R2 and inhibits ALDH1A1, ALDH2, and ALDH3A1 at 
similar levels. Compounds 31 and 32 both appear to selectively inhibit ALDH1A1, though 31 
only inhibits 50% at 10µM most likely due to the large N-phenylacetamide group at R2. 
Compoudn 32 contains a diethylamine in the same position and inhibits ALDH1A1 ~85% at 10 
µM. The last analogs went beyond altering the methyl 2-methoxypropanoate group or adding to 
the ring structure (33-37). Three of these compounds showed selectivity towards either 
ALDH1A1 or ALDH2. Compounds 34, which added a methane sulfonyl at R2 and a benzyl 
group at R6, and 37, which added isobutyramide at R3, selectively inhibited ALDH1A1 and 36, 
which replaced the methyl 2-methoxypropanoate group with a hydrogen at R2 and added a 
bromine at R3 and ketoxime at R6, selectively inhibited ALDH2. Of the 33 analogs tested, seven 
showed potential selectivity for ALDH2 based off activity at 10 µM compound (7, 9, 10, 11, 23, 
26, and 36) and two compounds showed selectivity and potency towards ALDH1A1 (32 and 34). 
These nine compounds, as well as the strong ALDH1A1 and ALDH2 inhibitor, 15, were selected 
for further analysis. 
Due to the hydrophobic nature of the substrate binding site within the free enzyme species of 
ALDH2, the logP values for the 33 analogs in addition to the initial four hits were examined 
(Tables 3 and 4). No direct correlation between logP values and inhibition of ALDH1A1 or 
ALDH2 could be discerned. 
EC50 Determination of Selected Analogs 
EC50 values were measured in regards to ALDH1A1, ALDH2, and ALDH3A1 for the ten 
selected compounds. Three compounds were excluded from further study for one of two reasons 
(Table 5). Both 9 and 23 are selective for ALDH2 (IC50= 0.15 ± 0.01 µM for each) but only 
partially inhibit the enzyme. We sought complete inhibitors of the isoenzymes so these analogs 
were not pursued further. Compound 26 was selective for ALDH2 versus ALDH1A1; however 
the compound was not characterized further as it partially inhibited ALDH3A1 activity. 
 
Table 5 IC50 values for four analogs with ALDH1A1, ALDH2, and ALDH3A1. Values are the 
mean/SEM of three independent experiments (n=3). 
Compound Structure 
IC50 (µM) 
ALDH1A1 ALDH2 ALDH3A1 
9 
O OO
 
NI 0.15 ± 0.01# NI 
23 
OO
O  
NI 0.15 ± 0.01# NI 
26 
O O O O
 
NI 0.47 ± 0.02 5.4 ± 1.0# 
#50-60% max inhibition 
NI= No inhibition 
The seven remaining compounds did not inhibit ALDH3A1 and fully inhibited ALDH1A1 
and/or ALDH2. For these compounds EC50 values for ALDH1B1, ALDH1A2, and ALDH1A3 
were also calculated in addition to those for ALDH1A1, ALDH2, and ALDH3A1 (Table 6).  
 
 
 
 
 
Table 6 EC50 values were calculated for seven analogs with the ALDH1A/2 family of 
isoenzymes in addition to ALDH3A1. AC50 curves had a maximum activity of ~200% control. 
Values are the mean/SEM of three independent experiments (n=3).  
Compound Structure 
IC50 (µM) 
ALDH2 ALDH1B1 
ALDH
1A1 
ALDH
1A2 
ALDH
1A3 
ALDH
3A1 
Daidzin 
O O O
OH
OOH
OHHO
OH  
3.5 ± 
0.1 
5.1 ± 
0.5 >200 
4.5 ± 
0.6 >200 NI 
7 
O OO
 
0.36 ± 
0.03 
0.086 
± 
0.002 
NI 
0.069 
± 
0.009 
 AC50     
0.87 ± 
0.09 
NI 
10 
O OO
 
0.067 ± 
0.006 
0.095 
± 
0.015 
0.13 ± 
0.01# 
0.065 
± 
0.004 
NI NI 
11 
O OO
 
0.067 ± 
0.003 
0.16 ± 
0.01 
0.17 ± 
0.02# 
0.13 ± 
0.01 
0.17 ± 
0.02# NI 
15 
O OO
O
N
 
2.0 ± 
0.2 
2.6 ± 
0.3 
0.13 ± 
0.01 
1.6 ± 
0.1 14 ± 1 NI 
32 
OON
 
NI NI 0.76 ± 0.07 >10 NI NI 
34 
OO
S
O
O
 
NI 13 ± 1 2.8 ± 0.1 11 ± 1 10 ± 1 NI 
36 
OO
Br
N
OH
 
4.6 ± 
0.6 NI NI NI 
 AC50        
35 ± 3 NI 
#50-60% max inhibition 
NI= No inhibition 
 
 
 
Compounds 7, 10, and 11 had IC50 values for the ALDH1/2 family of isoenzymes very similar to 
the psoralen derivatives found through the high-throughput screen and were more potent than 
daidzin. No improvement to the selectivity for any one particular isoenzyme of the ALDH1/2 
family was seen from adding the cyclopentyl, cyclcohexyl, or propyl group to the psoralen 
backbone. These additional groups would fit between Trp177 and Met174 in ALDH2, both of 
which are conserved throughout the ALDH1/2 family (Figure 2E). Compound 7 most likely 
doesn’t inhibit ALDH1A1 due to the lack of the longer alkyl chain at R6 to anchor itself in the 
larger pocket. Compound 15 showed a ~10-fold preference towards inhibiting ALDH1A1 (IC50 
= 0.13 ± 0.01 µM) versus the other four ALDH1A/2 isoenzymes. Compound 32 was found to be 
selectively inhibit ALDH1A1 (IC50=0.76 ± 0.07 µM) with only minor effects on ALDH1A2. 
Compound 34 showed a preference towards ALDH1A1 (IC50=2.8 ± 0.1 µM) while also 
inhibiting ALDH1B1, ALDH1A2, and ALDH1A3 activity. 34 had no measurable effect on the 
activity of ALDH2. 36 selectively inhibited ALDH2 (IC50=4.6 ± 0.5 µM) while also exhibiting 
two-fold activation of ALDH1A3 (AC50= 35 ± 3 µM). The inhibition properties of 15, 32, 34, 
and 36 were further explored through crystallographic and kinetic studies. 
Characterization of Compound 15 Binding 
The structure of 15 bound to ALDH1A1 was solved to a resolution of 1.70Å (Table 2). The 
structure shows that 15 binds within the substrate binding site of ALDH1A1 (Figure 4A). 
However, the psoralen backbone of 15 has shifted relative to the position of 2 bound to ALDH2 
and is bound between Tyr297, Gly458, His293, and Phe290. As a consequence of this shift, the 
piperidine ring of the longer linker structure of 15 is positioned near the catalytic cysteine. 
Unlike the alkyl chain of 2, the piperidine ring in this position does not approach the NAD(H) 
binding site (Figures 3B and 4B). Covariation experiments were used to evaluate the 
mechanistic differences between the binding of 15 to ALDH1A1 and to ALDH2. 15 was found 
to exhibit uncompetitive inhibition (Ki =170 ± 13 nM) towards varied NAD+ for ALDH1A1, 
which is consistent both with the distance between the NAD+ and 15 binding sites in ALDH1A1 
and is expected for compounds that displace aldehyde substrates for ordered Bi Bi systems 
(Figure 4C). Uncompetitive inhibition would suggest that 15 binds only to the enzyme-
coenzyme complex and not to the free enzyme. However, the structural data of 15 bound to the 
free enzyme appears to contradict the kinetic data, but the concentration ranges utilized for the 
two experiments did not overlap. The concentration of 15 used in the crystallography experiment 
was 400-fold times the highest concentration utilized in the kinetic experiment (200 µM vs 0.5 
µM). Thus, 15 appears to also bind to the free enzyme, but under the conditions of the steady-
state kinetic experiments, this complex formation is kinetically insignificant and yields an 
uncompetitive pattern. A similar pattern of uncompetitive inhibition towards varied coenzyme in 
a kinetic experiment, compared to a complex between the free enzyme and inhibitor, was also 
observed with daidzin and ALDH2.36, 37 Interestingly, 15 exhibited competitive inhibition (Ki= 
1.1 ± 0.1 µM) towards varied NAD+ for ALDH2 (Figure 4D). This result is similar to the 
mechanism exhibited by 2, suggesting 15 retains a binding relationship similar to 2 bound to 
ALDH2. These data would infer that the psoralen substructure of 15 binds to ALDH2 with the 1-
acylpiperidine extending past Cys302 and posed toward the NAD+ site, consistent with its 
competitive mode of inhibition. However, for ALDH1A1 the presence of Gly458 and its larger 
substrate binding pocket promotes a shift in binding mode and mechanism of inhibition for 15. 
The residue corresponding to Gly458 in the other four ALDH1/2 isoenzymes is either an 
asparagine or aspartate (D457 in ALDH2) which precludes the binding mode observed in 
ALDH1A1. 
Figure 4 – Binding characteristics of compound 15. (A) Electron density map of 15 bound to 
ALDH1A1 with the original figure-of-merit weighted Fo-Fc map in green contoured at 2.5 
standard deviations and the original figure-of-merit weighted 2Fo-Fc map in blue contoured at 1.0 
standard deviation obtained after initial refinement before addition of solvent or ligand to the 
structure factor calculations. (B) Comparison of binding modes of 15 (black) bound to 
ALDH1A1 (orange) and 2 (yellow), NADH (green), and NAD+(purple) bound to ALDH2 
(cyan). NAD+/NADH binding positions obtained from PDB1O02 and 1O04. (C) Lineweaver-
Burk representation of the uncompetitive inhibition pattern for 15 versus varied NAD+ for 
ALDH1A1 at saturating concentrations of propionaldehyde (1 mM). (D) Lineweaver-Burk 
representation of competitive inhibition for 15 versus varied NAD+ with ALDH2 at saturating 
concentration of propionaldehyde (1 mM). Values are the mean/SEM of three independent 
experiments (n=3). 
 
 
Characterization of Compound 34 Binding 
The structure of the coumarin derivative 34 bound to ALDH1A1 was solved to a resolution of 
1.70 Å (Table 2). 34 binds within the substrate binding site (Figure 5A) and the lactone 
carbonyl is oriented towards the catalytic cysteine though not close enough to form a hydrogen 
bond like 2 in ALDH2 (Figure 5B). Although the electron density for the benzyl group of 34 
was diffuse, the movement of Trp178 was reminiscent of the interaction between CM037 and 
ALDH1A1 in the same region, which also resulted in more diffuse density in this region.49 The 
additional benzyl group prevents the compound from binding closer to the catalytic cysteine. 34 
does not inhibit ALDH2 and the mode of binding provides insight into this selectivity. The 
methane sulfonyl group of 34 binds in the pocket formed by Gly458 in ALDH1A1. This 
additional space only exists in ALDH1A1. The corresponding aspartate/asparagine residues in 
the other ALDH1/2 isoenzymes would force the coumarin scaffold to adopt a position like 2 in 
ALDH2. However, unlike the flexible linker in 15, the large benzyl ring proximal to the lactone 
cannot adopt a conformation to productively bind within the NAD+-binding cleft and the benzyl 
ring of 34 would encounter more steric hindrance from as the conserved tryptophan (Trp177 in 
ALDH2) since the residues surrounding Trp177 are bulkier in ALDH2. 
 
Figure 5 – Binding mode of compound 34. (A) Electron density map of 34 bound to 
ALDH1A1 with the original figure-of-merit weighted Fo-Fc map in green contoured at 2.5 
standard deviations and the original figure-of-merit weighted 2Fo-Fc map in blue contoured at 1.0 
standard deviation obtained after initial refinement before addition of solvent or ligand to the 
structure factor calculation. (B) Overlay of 34 (black) bound to ALDH1A1 (orange) and 2 
(yellow) bound to ALDH2 (cyan). 
 
 
 
 
Characterization of Compound 32 Binding 
The structure of compound 32 bound to ALDH1A1 was solved to a resolution of 2.05Å, with the 
ligand modeled at full occupancy in each of the eight monomers (Table 2). Surprisingly, 32 
binds in the coenzyme binding cleft of ALDH1A1 (Figure 6A) between Pro227 and Val250 in a 
position similar to the adenine ring of NAD+ (Figure 6B).  The fact that 32 bound in the 
coenzyme binding site ALDH1A1 and the fact the crystal formed in a unique space group (P1) 
raises the possibility that the binding site might be influenced by the crystal environment. 
However, there are structural reasons for the selectivity between ALDH2 and ALDH1A1 in this 
binding location which suggest that binding within the coenzyme site is not an artifact of this 
particular crystal form (Figure 7). There are three amino acid substitutions of residues that 
directly contact 32 between ALDH1A1 and ALDH2.  In particular, Ile249 in ALDH2 is Val250 
in ALDH1A1 and although it is the addition of a single methyl group, the substitution narrows 
this side of the site enough to impede binding of the diethylamino substituent in ALDH2. In 
addition, Val252 and Ala233 in ALDH2 versus Leu253 and Ser234 in ALDH1A1 may loosen 
the contacts between the enzyme and 32 on the side away from Ile249 sufficiently that the 
binding energetics cannot overcome the steric clash at 249 through small shifts toward this side 
of the binding cleft.  Covariation experiments were completed to further characterize the 
interaction of 32 with ALDH1A1. If 32 was bound to the NAD+ binding site as seen in the 
crystal structure the inhibition profile versus varied NAD+ would be predicted to be competitive. 
Surprisingly, 32 was found to be noncompetitive versus varied NAD+ for ALDH1A1 with 
Ki=1.2 ± 0.1 µM and noncompetitive versus varied acetaldehyde for ALDH1A1 with Ki = 0.87 ± 
0.04 µM (Figure 6C) Although noncompetitive inhibition versus NAD+ is inconsistent with the 
binding of 32 to the NAD+ site, it is also a different mode of inhibition from compounds 
determined to bind in the substrate binding site, 2 (competitive) and 15 (uncompetitive), which 
suggests 32 binds differently than these other analogs. A similar compound to 32 was also tested 
to support the kinetic data of 32. 30 is a coumarin derivative which essentially replaces the 
diethylamine of 32 with a terminal cyano group. 30 inhibits both ALDH1A1 and ALDH2 as 
Ile249 in ALDH2 does not provide selectivity against the linear cyano group in this binding 
position. 30 was found to be noncompetitive versus varied NAD+ for ALDH1A1 and be 
noncompetitive (mixed-type) versus varied NAD+ for ALDH2 (Figure 6D) which is consistent 
with the inhibition mode of 32. The reason behind the discrepancy between the kinetic data and 
structural data remains unclear. There is a possibility that 32 could bind to a different location in 
the enzyme when NAD+ is present, and when NAD+ is absent (as in the case of the structure) the 
compound prefers to bind in the NAD+ binding site. The possibility of multiple binding sites is 
supported by the compound exhibiting noncompetitive inhibition towards varied NAD+ or varied 
substrate (Figure 6C). This additional site could be the substrate binding site where 34, another 
coumarin derivative, binds. 
 
Figure 6 – Binding characteristics of substituted coumarins. (A) Representative electron 
density map of 32 bound to ALDH1A1 with the original figure-of-merit weighted Fo-Fc map in 
green contoured at 2.5 standard deviations and the original figure-of-merit weighted 2Fo-Fc map 
in blue contoured at 1.0 standard deviation obtained after initial refinement before addition of 
solvent or ligand to the structure factor calculations. (B) Overlay of 32 and NADH (PDB 4WB9) 
bound to ALDH1A1 (C) Lineweaver-Burk representation of noncompetitive inhibition for 32 
versus varied NAD+ with ALDH1A1 at saturating concentrations of propionaldehyde (1 mM) 
and noncompetitive inhibition for 32 versus varied acetaldehyde at saturating concentrations of 
NAD+ (1 mM).(D) Lineweaver-Burk representations of noncompetitive inhibition for 30 versus 
varied NAD+ with ALDH1A1 and of noncompetitive inhibition (mixed-type) inhibition for 30 
with varied NAD+ with ALDH2 at saturating concentrations of propionaldehyde (1 mM). Values 
are the mean/SEM of three independent experiments (n=3). 
 
Figure 7 – Selectivity for 32. Comparison of binding of 32 (black) to ALDH1A1 (purple) 
overlayed onto the equivalent region of ALDH2 (green). The non-conserved residues between 
ALDH1A1 and ALDH2 are labeled. 
 
Characterization of Compound 36 Binding to ALDH2 
Compound 36 was the lone ALDH2-selective compound (apart from 4) discovered in this study. 
Covariation experiments were performed to determine how 36 inhibits ALDH2 in part due to the 
diverse inhibition profile of the other compounds towards ALDH1A1. 36 was found to 
competitively inhibit the binding of NAD+ to ALDH2 with a Ki = 2.4 ± 0.1 µM (Figure 8). This 
result suggests that 36 also alters the conformation of the catalytic cysteine interfering with the 
productive binding of NAD+ for catalysis similar to 2 and 3. If 36 were to adopt a similar 
conformation to that of 2, the ketoxime would occupy the same pocket as the propyl chain. The 
bromine would be oriented towards Met174 which could lead to a favorable interaction between 
the halogen substituent and the sulfur side chain atom. This potential interaction is not possible 
for the three ALDH1A isoenzymes since a glycine occupies the equivalent position. However, it 
is unclear what effect the equivalent glutamate in ALDH1B1 would have on 36 binding. The 
glutamate of ALDH1B1 could provide additional contacts for 36 binding, thus the rationale for 
selectivity towards ALDH2 by 36 is still unclear. 
 
Figure 8 - Lineweaver-Burk representation of competitive inhibition for 36 versus varied NAD+ 
with ALDH2 at saturating concentrations of propionaldehyde (1 mM). Values are the mean/SEM 
of three independent experiments (n=3) 
 
 
Aromatic Binding Regions of ALDH1A1 and ALDH2 
Since the binding modes and kinetic data are distinct for particular compound/enzyme pairs, we 
reasoned that aspects of the substrate binding sites and differences in kinetic mechanism underlie 
these differences. In particular, structural comparisons of the three compound-enzyme complexes 
with compound in the substrate binding site highlighted the presence of two distinct aromatic 
binding “boxes” or “slots” (Figure 9). In ALDH2 the aromatic binding region is located between 
four phenylalanine residues (170, 296, 459, 465) near the catalytic cysteine and surround 2. The 
isoflavone of the ALDH2 inhibitor daidzin binds in the same aromatic region as does the 
activator Alda-1.37, 50 The aromatic binding region of ALDH1A1 is wider, extends farther from 
the catalytic cysteine and is more surface exposed.  Of the four phenylalanine residues near the 
catalytic cysteine in ALDH2, Phe459 is replaced by a valine and Phe296 is replaced by a 
tyrosine. The aromatic binding region of ALDH1A1 has additional aromatic residues at His293 
and Phe290. The corresponding residues in ALDH2 are Phe292 and Gln289. Although Phe292 
in ALDH2 is aromatic, the side chain of Asp457 blocks any connection of the two binding sites, 
which makes the binding region in ALDH2 smaller than that in ALDH1A1, though the two 
regions do overlap.  Compounds have the ability to bind throughout the aromatic region in 
ALDH1A1 due to Gly458, as previously described for the ALDH1A1 inhibitors CM037 and 
CM026.49 
 
Figure 9  - Distinct aromatic binding boxes of ALDH1A1 and ALDH2. Compound 2 bound 
to ALDH2 shown in green. Compound 15 bound to ALDH1A1 shown in cyan. Compound 34 
bound to ALDH1A1 shown in purple. 
 
A second aromatic binding pocket exists in ALDH isoenzymes, namely the adenine binding cleft 
within the coenzyme binding site, where the adenine ring is positioned between a conserved 
proline (Pro227 in ALDH1A1) and beta-branched amino acid (Val250 in ALDH1A1). However, 
there is only one aromatic amino acid within this structural element (Phe244) with the remainder 
being primarily aliphatic side chains. Consequently, while the site is hydrophobic, there are 
fewer aromatic groups present in this region than in the substrate binding site which may reflect 
the more hydrophilic nature of the adenosine group of NAD+ and lead to greater partitioning into 
the substrate site for most of these compounds.  However, the structure of 32 shows that at least 
one of the compounds presented in this work can bind to the adenine site. Although, the kinetic 
data support binding at an additional site, most likely the aromatic binding region in the substrate 
binding site. 
CONCLUSION 
Selective compounds for the individual members of the ALDH1/2 family of isoenzymes would 
be useful in determining their relative contributions to biological function. This study 
characterized a series of aromatic lactones which inhibit the ALDH1/2 family with the goal of 
developing an ALDH2-selective inhibitor. The agreement between the structure activity 
relationships and structural studies show the interactions are both specific and selective. The 
psoralen and coumarin analogs take advantage of multiple aromatic binding regions of the 
ALDH1/2 isoenzymes. Although psoralen and coumarin derivatives can form Michael additions, 
all but two compounds tested have at least a methyl group at position R5 preventing such a 
reaction and thus eliminating the possibility of covalent inhibition by this means. Additionally, 
the kinetic and structural data demonstrate a non-covalent means of inhibition. Aromatics can 
bind within the hydrophobic substrate binding site as well as the NAD+ binding site. The size of 
the compound and the neighboring residues help determine to which of the sites the compounds 
bind.  
The differing binding modes of the derivatives make it somewhat challenging to predict where 
compounds will bind though some basic observations can be applied. The small coumarin 
analogs can bind in the NAD+ binding site like 32, but once they reach a size threshold the 
compounds prefer the substrate binding site (e.g. 34). The absence of an amino acid side chain at 
Gly458 in ALDH1A1 allows for a larger aromatic binding area, best exemplified by 15. The 
unique aromatic binding regions linked to topological differences allow the same coumarin ring 
structure to be selective for different isoenzymes as substituents are varied to better match the 
target enzyme’s structural features. 
Surprisingly, 32 achieves selectivity towards ALDH1A1 by binding in the more highly 
conserved adenine binding site. Our initial screen was designed to avoid compounds which 
bound in the NAD+ binding site as we reasoned these would have lower selectivity. 32 shows 
that selectivity is possible through binding in this location. 36 achieves selectivity towards 
ALDH2 while competitively inhibiting the productive binding of NAD+. Although the exact 
binding location of 36 is unknown, the compound most likely binds in similar position to 2 in the 
substrate binding pocket. 36 inhibits ALDH2 with similar IC50 values to daidzin in vitro and is 
more selective. Daidzin, previously described as an ALDH2-seletive inhibitor, inhibited the 
activity of three of the five ALDH1/2 isoenzymes. Several additional derivatives in this study 
improve upon daidzin’s potency towards the ALDH1/2 isoenzymes in our assays. Future 
experiments will consist of further developing structure-activity relationships for 32 and 36 and 
determining their effects in various cellular models. 
EXPERIMENTAL SECTION 
Materials 
All materials were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. 
Compounds purchased from ChemDiv Corporation (San Diego, CA) and ChemBridge 
Corporation (San Diego, CA) were >95% pure based on the spectra (either NMR or LC/MS) 
provided by the vendor. Following receipt from the vendor, their chemical identities were further 
verified by LC/MS to check for correct molecular weight in the Department of Chemistry, 
Indiana University-Purdue University, Indianapolis, IN or the Chemical Genomics Core Facility, 
Indiana University School of Medicine, Indianapolis, IN and used without further purification. 
Compound 22, purchased from Sigma-Aldrich, was not checked for purity by the company and 
daidzin, purchased from TZS Scientific LLC (Framingham, MA), was >99% pure by their 
analysis, though with no accompanying spectra. For both of these compounds, the purity was 
checked by LC/MS and NMR in the Chemical Genomics Core Facility, Indiana University 
School of Medicine, Indianapolis, IN. 
Expression of ALDH isoenzymes 
Human ALDH1A1, ALDH1A2, ALDH2, ALDH1B1, ALDH3A1, and rat ALDH1L1 were 
prepared and purified as previously described.25, 39, 51, 52  Human ALDH1A3 was prepared by one 
of two protocols. The first was by using the previous described method which yielded very little 
protein for enzymatic study.52 The second was using a His-tagged construct for full length 
ALDH1A3 generously provided by Jaume Farres which was subcloned into the pET-30Xa/LIC 
expression plasmid. His-tagged ALDH1A3 was produced and purified as previously described 
for ALDH3A1, except only a single passage on a nickel-NTA column was used for 
purification.39 The two ALDH1A3 constructs behaved similarly when used in kinetic 
experiments. 
Compound Inhibition and IC50 Determination 
Inhibition of ALDH isoenzymes by the compounds and the respective IC50 curves were 
determined by measuring the formation of NAD(P)H spectrophotometrically at 340 nm (molar 
extinction coefficient of 6220 M-1 cm-1) on a Beckman DU-640 spectrophotometer using purified 
recombinant enzyme. All assays were performed at 25° C and were initiated by addition of the 
substrate after a 2 min incubation period. The assay components for these selectivity assays were 
designed to provide the maximal stringency toward ALDH2 such that the substrate concentration 
utilized was >500-fold above KM for ALDH2 while keeping below 15-fold over KM for the other 
isoenzymes.43 For the ALDH1A family members and ALDH2, the assay included 100-200 nM 
enzyme, 200 µM NAD+, 100 µM propionaldehyde (KM values ~100 nM for ALDH241, ~50 µM 
for ALDH1A153 ,ALDH1A254, and KM value for ALDH1A3 determined empirically by varying 
propionaldehyde concentration41), and 1% DMSO in 25 mM BES buffer, pH 7.5. The assay for 
ALDH1B1 used 500 µM NAD+ and 200 µM propionaldehyde (KM ~ 14 µM)55. For ALDH4A1 
the assay included 500 µM NAD+ and 20 mM propionaldehyde (KM ~ 9 mM)56. For ALDH5A1 
the assay included 200 µM NAD+ and 2 mM propionaldehyde (KM ~ 600 µM)57. For ALDH1L1 
the assay included 500 µM NADP+ and 4 mM propionaldehyde (KM ~ 700 µM)58. For 
ALDH3A1, the assay included the commonly utilized substrate benzaldehyde at 300 µM (KM 
~200 µM)59 alongside 300 µM NADP+, 20 nM ALDH3A1 and 1% DMSO. Assays for 
ALDH3A1, ALDH4A1, and ALDH5A1 were performed in 100 mM sodium phosphate buffer, 
pH 7.5. All compounds were soluble in assays up to 100 µM and did not interfere with the 
analytical output measured by the assays unless otherwise noted. Data were fit to the four 
parameter EC50 equation using SigmaPlot (v12) and the values represent the mean/SEM of three 
independent experiments (each n=3).  
Selection and Characterization of Analogs of Initial Inhibitors 
Thirty-three additional psoralen and coumarin derivatives were ordered from ChemDiv, 
ChemBridge, and Sigma-Aldrich to build structure-activity relationships. Compounds were 
initially tested for their effect on the oxidation of aldehyde substrate by ALDH1A1, ALDH2, and 
ALDH3A1. Compounds which showed potential selectivity for ALDH1A1 or ALDH2 were 
examined further by measuring EC50 values for each of the three enzymes. EC50 curves for 
ALDH1A2, ALDH1A3, and ALDH1B1 inhibition were determined for compounds which 
continued to show selectivity towards ALDH2 or ALDH1A1. Data were fit to the four parameter 
EC50 equation using SigmaPlot (v12) and the values represent the mean/SEM of three 
independent experiments.  
Steady-State Kinetic Characterization with ALDH1A1 and ALDH2 
The mode of inhibition towards varied coenzyme (NAD+) was determined via steady-state 
kinetics by varying inhibitor and coenzyme concentrations at fixed substrate concentrations. 
Dehydrogenase activity was measured spectrophotometrically by measuring the formation of 
NADH at 340 nm (molar extinction coefficient of 6220 M-1 cm-1) on a Beckman DU-640 
spectrophotomer. All assays included 100 – 200 nM enzyme, 1 mM propionaldehyde, and 1% 
DMSO in 25 mM BES buffer, pH 7.5 at 25°C. For ALDH2 ranges of 15 – 400 µM NAD+ and 
either 0 – 100 nM 2, 0 – 1 µM 3, 0 – 2 µM 4, 0 – 10 µM 15, 0 – 50 µM 30, or 0 – 10 µM 36 
were used. For ALDH1A1 ranges of 20 – 200 µM NAD+ and either 0 – 500 nM 15, 0 – 50 µM 
30, or 0 – 4 µM 32 were used. The mode of inhibition of 32 toward varied acetaldehyde was 
determined via steady-state kinetics by varying inhibitor and substrate concentrations at fixed 
coenzyme concentrations. Assays included 300 nM ALDH1A1, 1 mM NAD+ , 30 — 500 µM 
acetaldehyde, 0  – 1.5 µM 32, and 1% DMSO in 25 mM BES buffer, pH 7.5 at 25°C. All data 
were fit to the tight binding or single substrate-single inhibitor non-linear velocity expressions 
for competitive, non-competitive, mixed type non-competitive, and uncompetitive inhibition 
using SigmaPlot (v12, Enzyme Kinetics Module) to evaluate goodness of fit. Lineweaver-Burk 
plots were generated using SigmaPlot(v12) to better visualize the inhibition. All data represent 
the mean/SEM of at least three independent experiments (each n=3). 
Crystallization of ALDH1A1 and ALDH2 in Complex with Compounds 
Crystals of ALDH2 in complex with 2 were grown by equilibrating 8 mg/mL ALDH2 and 200 
µM 2 in 2% DMSO with 100 mM Na-ACES, pH 6.4, 100 mM guanidine-HCl, 10 mM MgCl2, 4 
mM dithiothreitol, and 18% PEG 6000. Crystals of ALDH1A1 were grown by equilibrating 3 
mg/mL ALDH1A1 with 100mM Na-BisTris, pH 6.2 – 6.6, 9 – 11% PEG3350, 200 mM NaCl, 
and 5 mM YbCl3. Crystals of ALDH1A1 in complex with 15 and 32 were grown in the presence 
of 200µM compound and 2% (v/v) DMSO (co-crystallization). The crystal of ALDH1A1 in 
complex with 34 was prepared by soaking an apo-ALDH1A1 crystal overnight with 
crystallization solution containing 500 µM 34 with 2% (v/v) DMSO. Crystals were cryoprotected 
for flash-freezing with 18% (v/v) ethylene glycol for ALDH2 and 20% (v/v) ethylene glycol for 
ALDH1A1. Diffraction data were collected at Beamline 19-ID operated by the Structural 
Biology Consortium at the Advanced Proton Source (APS), Argonne National Laboratory. 
Diffraction data were indexed, integrated, and scaled using HKL2000 or HKL3000 program 
suites.60 HKL2000 version 0.96 was used for the structure of ALDH2 in complex with 2, 
HKL2000 version 706 was used for the structures of ALDH1A1 in complex with 15 and 34, and 
HKL3000 version 712 was used for the structure of ALDH1A1 in complex with 32. The CCP4 
program suite was used for molecular replacement and refinement with the human apo-ALDH2 
structure (PDB Code 3N80) as a model for ALDH2 and human apo-ALDH1A1 structure ( PDB 
Code 4WJ9) for ALDH1A1.61 The Coot molecular graphic application was used for model 
building.62 An oxidized cysteine residue (CSO) was modeled in the active site at position 303 for 
the structures of ALDH1A1 in complex with 15 and 34. The TLSMD 
(Translation/Libration/Screw Motion Determination) server was used to determine dynamic 
properties of ALDH1A1.63, 64 
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S2
Compound 1 (2CB5) 3,5-dimethyl-6-propyl-7H-furo[3,2-g]chromen-7-one 
 
Compound 2 (2P3) 2,3,5-trimethyl-6-propyl-7H-furo[3,2-g]chromen-7-one 
 
 
S3
Compound 3 (2P4) 2,3,5,6-tetramethyl-7H-furo[3,2-g]chromen-7-one 
 
 
Data File D:\DATA\2084\2FJ-5501.D 
Sample Name: CH006843P2-F-10 
Instrument 1 31/07/2011 12:54:11  #6 
Column: Onyx C18 50x4.6mm | 3.75ml/min | Columns Reg Valve 
Gradient: "A"->@2.2min->"B"(Hold 0.4min)->@0.2min->"A"->PostRun 
PMP1, Solvent A         : 0.1%TFA in Acn/H2O (2.5:97.5) 
PMP1, Solvent B         : 0.1% TFA in AcN 
PMP1, Solvent C         : 0.1%FA in ACN/H2O (2.5:97.5) 
PMP1, Solvent D         : 0.1%FA in ACN 
Ionization mode             :    APCI Positive 
 
Signal 1: ADC1 A, ELSD 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mV*s]      [mV]         % 
----|-------|----|-------|----------|----------|--------| 
   1   1.856 BP    0.0466  352.23938  120.55231 100.0000 
Totals :                   352.23938  120.55231 
 
 
Signal 2: DAD1 A, Sig=300,200 Ref=off 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
   1   1.797 PP    0.0530 6375.53760 1907.58130 100.0000 
Totals :                  6375.53760 1907.58130 
 
 
Signal 3: MSD1 TIC, MS File 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]                            % 
----|-------|----|-------|----------|----------|--------| 
   1   1.850 PP    0.0580 2.89504e7  6.70729e6  100.0000 
Totals :                  2.89504e7  6.70729e6  
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S5
Compound 4 (2BS4) methyl 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)propanoate 
 
Compound 5 3-(tert-butyl)-5,6-dimethyl-7H-furo[3,2-g]chromen-7-one 
 
S6
Compound 6 2,3,5,6,9-pentamethyl-7H-furo[3,2-g]chromen-7-one 
 
Compound 7 2,3-dimethyl-5-propyl-7H-furo[3,2-g]chromen-7-one 
 
S7
Compound 8 3,4-dimethyl-6,7,8,9-tetrahydro-2H-benzofuro[3,2-g]chromen-2-one 
 
Compound 9 9,10-dimethyl-5H-benzo[c]furo[3,2-g]chromen-5-one 
 
S8
Compound 10 9,10-dimethyl-1,2,3,4-tetrahydro-5H-benzo[c]furo[3,2-g]chromen-5-one 
 
Compound 11 8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g]chromen-4(1H)-one 
 
 
Data File R:\HPLC\AUTO\CH006848\2AF-2401.D 
Sample Name: CH006848P2-A-06 
Instrument 1 05/08/2011 15:28:25   
PMP1, Solvent A         : 0.1%TFA in Acn/H2O (2.5:97.5) 
PMP1, Solvent B         : 0.1% TFA in AcN 
PMP1, Solvent C         : 0.1%FA in ACN/H2O (2.5:97.5) 
PMP1, Solvent D         : 0.1%FA in ACN 
Ionization mode             :    API-ES Positive 
 
Signal 1: ADC1 A, ELSD 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mV*s]      [mV]         % 
----|-------|----|-------|----------|----------|--------| 
   1   1.999 MM    0.0598  160.98053   44.86544 100.0000 
S9
Totals :                   160.98053   44.86544 
 
 
Signal 2: DAD1 A, Sig=300,200 Ref=off 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
   1   1.920 MM    0.0766 4118.46436  896.05463 100.0000 
Totals :                  4118.46436  896.05463 
 
 
Signal 3: MSD1 TIC, MS File 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]                            % 
----|-------|----|-------|----------|----------|--------| 
   1   1.973 MM    0.0850 3.55092e7  6.96126e6  100.0000 
Totals :                  3.55092e7  6.96126e6  
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S10
Compound 12 6-benzyl-3,5-dimethyl-7H-furo[3,2-g]chromen-7-one 
 
Compound 13 5,6-dimethyl-3-phenyl-7H-furo[3,2-g]chromen-7-one 
 
 
S11
Compound 14 2,3-dimethyl-5-phenyl-7H-furo[3,2-g]chromen-7-one 
 
Compound 15 2,3,5-trimethyl-6-(3-oxo-3-(piperidin-1-yl)propyl)-7H-furo[3,2-g]chromen-7-one 
 
 
S12
Compound 16 N-benzyl-3-(2,3,5-trimethyl-7-oxo-7H-furo[3,2-g]chromen-6-yl)propanamide 
 
Compound 17 4-methyl-7-((3-oxobutan-2-yl)oxy)-2H-chromen-2-one 
 
 
 
 
S13
Compound 18 4-methyl-7-(2-oxopropoxy)-2H-chromen-2-one 
 
Compound 19 7-((3-oxobutan-2-yl)oxy)-2H-chromen-2-one 
  
 
S14
Compound 20 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetamide 
 
 
S15
Compound 21 7-methoxy-4-methyl-2H-chromen-2-one 
 
Compound 22 2-((2-oxo-2H-chromen-7-yl)oxy)propanoic acid   (None) 
Compound 23 3,4,8,9-tetramethyl-7H-furo[2,3-f]chromen-7-one 
 
 
Data File R:\HPLC\AUTO\CR006614\1FA-0601.D 
Sample Name: CR006614P1-F-01 
Instrument 1 09/11/10 15:32:25   
PMP1, Solvent A         : 0.1%TFA in MeOH/H2O (2.5:97.5) 
S16
PMP1, Solvent B         : 0.1% TFA in MeOH 
PMP1, Solvent C         : 0.1%FA in ACN/H2O (2.5:97.5) 
PMP1, Solvent D         : 0.1%FA in ACN 
Ionization mode             :    API-ES Positive 
 
Signal 1: ADC1 A, ELSD 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mV*s]      [mV]         % 
----|-------|----|-------|----------|----------|--------| 
   1   1.877 PB    0.0605    3.61876 8.36813e-1 100.0000 
Totals :                     3.61876 8.36813e-1 
 
 
Signal 2: DAD1 A, Sig=300,200 Ref=off 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
   1   1.812 MM    0.1051 5279.57227  836.94751 100.0000 
Totals :                  5279.57227  836.94751 
 
 
Signal 3: MSD1 TIC, MS File 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]                            % 
----|-------|----|-------|----------|----------|--------| 
   1   1.862 MM    0.1160 2.97291e7  4.27207e6  100.0000 
Totals :                  2.97291e7  4.27207e6  
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S18
Compound 24 3-methyl-2H-furo[2,3-h]chromen-2-one 
 
 
 
 
 
 
 
 
 
 
 
 
S19
Compound 25 3,4,10-trimethyl-2H,6H-pyrano[3,2-g]chromene-2,6-dione 
 
 
Data File D:\DATA\2170\2HJ-1101.D 
Sample Name: CH006462P2-H-10 
Instrument 1 05/06/2010 02:39:59  #2 
Column: Monolithic SpeedROD C18e 50x4.6mm | 3.75ml/min 
Gradient: "A"->@2.1min->"B"(Hold 0.8min)->@0.2min->"A"->PostRun 
PMP1, Solvent A         : 0.1%TFA in MeOH/H2O (2.5:97.5) 
PMP1, Solvent B         : 0.1% TFA in MeOH 
PMP1, Solvent C         : 0.1%FA in ACN/H2O (2.5:97.5) 
PMP1, Solvent D         : 0.1%FA in ACN 
Ionization mode             :    API-ES Positive 
 
Signal 1: ADC1 A, ELSD 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mV*s]      [mV]         % 
----|-------|----|-------|----------|----------|--------| 
   1   1.844 PB    0.0632   93.72084   19.79089 100.0000 
Totals :                    93.72084   19.79089 
 
 
Signal 2: DAD1 A, Sig=300,200 Ref=off 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
   1   1.792 PV    0.1532 1.59864e4  1302.10864  94.4741 
   2   2.469 VBA   0.0965  935.05847  126.11507   5.5259 
Totals :                  1.69214e4  1428.22371 
 
 
Signal 3: MSD1 TIC, MS File 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]                            % 
----|-------|----|-------|----------|----------|--------| 
   1   1.850 PB    0.1111 3.65060e7  4.25644e6  100.0000 
Totals :                  3.65060e7  4.25644e6  
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Compound 26 6-methyl-3,4-dihydro-2H,8H-pyrano[3,2-g]chromene-2,8-dione 
 
 
Data File R:\HPLC\AUTO\CH006839\1EH-6101.D 
Sample Name: CH006839P1-E-08 
Instrument 1 02/08/2011 12:25:49   
Column: Onyx C18 50x4.6mm | 3.75ml/min | Columns Reg Valve 
Gradient: "A"->@2.4min->"B"(Hold 0.2min)->@0.2min->"A"->PostRun 
PMP1, Solvent A         : 0.1%TFA in Acn/H2O (2.5:97.5) 
PMP1, Solvent B         : 0.1% TFA in AcN 
PMP1, Solvent C         : 0.1%FA in ACN/H2O (2.5:97.5) 
PMP1, Solvent D         : 0.1%FA in ACN 
Ionization mode             :    API-ES Positive 
 
Signal 1: ADC1 A, ELSD 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mV*s]      [mV]         % 
----|-------|----|-------|----------|----------|--------| 
   1   1.291 VB    0.0367  407.73862  168.95898 100.0000 
Totals :                   407.73862  168.95898 
 
 
Signal 2: DAD1 A, Sig=300,200 Ref=off 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
S22
----|-------|----|-------|----------|----------|--------| 
   1   1.071 MM    0.0288  260.57870  150.62273  10.1656 
   2   1.218 MM    0.0473 2260.34351  795.81219  88.1795 
   3   1.390 MM    0.0349   42.42276   20.23051   1.6550 
Totals :                  2563.34497  966.66544 
 
 
Signal 3: MSD1 TIC, MS File 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]                            % 
----|-------|----|-------|----------|----------|--------| 
   1   1.271 MM    0.0517 1.93388e7  6.22976e6  100.0000 
Totals :                  1.93388e7  6.22976e6 
S23
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Compound 27 7-(allyloxy)-4-methyl-2H-chromen-2-one 
 
Compound 28 4-methyl-7-((3-methylbut-2-en-1-yl)oxy)-2H-chromen-2-one 
 
 
 
 
S25
Compound 29 4-methyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one 
 
Compound 30 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetonitrile 
 
 
S26
Compound 31 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)-N-phenylacetamide 
 
Compound 32 7-(diethylamino)-4-methyl-2H-chromen-2-one 
 
 
 
S27
Compound 33 3-((3-oxobutan-2-yl)oxy)-6H-benzo[c]chromen-6-one 
 
 
 
Compound 34 3-benzyl-4-methyl-2-oxo-2H-chromen-7-yl methanesulfonate 
 
S28
Compound 35 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
S29
Compound 36 6-bromo-3-(1-(hydroxyimino)ethyl)-2H-chromen-2-one 
 
Compound 37 N-(4,7-dimethyl-2-oxo-2H-chromen-6-yl)isobutyramide 
 
Daidzin None 
S30
  
 
 
 
 
 
 
 
LC/MS Confirmation of Vendor Provided Compound Purity 
 
 
 
 
S31
Formula Flags (Tgt) Show/Hide Cpd Compound Number ID Source ID Techniques Applied Score Saturated Start RT End m/z Mass Mass (Tgt) Score (Tgt) Diff (Tgt, ppm) Diff (Tgt, mDa) Polarity Ions Min Z Max Z Z Count Height Area Abund Width Base Peak Algorithm Label Flag Severity (Tgt)
C16 H16 O3 TRUE 1 1 FBF FBF 95.3 0.254 0.384 0.527 279.0981 256.108 256.1099 95.3 -7.66 -1.96 Positive 6 1 1 1 18127 143794 9321 0.181 101.004 Find By Formula Cpd 1: C16 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C16 H16 O3 95.3 7.66 (M+H)+ (M+Na)+ 257.1125 279.0981
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
279.0981 (M+Na)+ 95.3 90.59 99.5 99.71 9394.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
279.0981 279.0992 3.86 9320.5 9394.7 100 100 83.6 82.9
280.1013 280.1026 4.42 1676.8 1653.8 18 17.6 14.7 14.9
281.1033 281.1052 6.73 245.8 194.7 2.6 2.1 1.7 2.2
257.1125 (M+H)+ 30.42 12.16 52 41.06 2605.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
257.1125 257.1172 18.36 2339 2605.6 100 100 83.5 75
258.1178 258.1206 10.78 591.2 459 25.3 17.6 14.7 19
259.1079 259.1233 59.13 188.5 54 8.1 2.1 1.7 6
C17 H18 O3 TRUE 1 2 FBF FBF 98.42 0.232 0.27 0.601 293.1154 270.1263 270.1256 98.42 2.66 0.72 Positive 6 1 1 1 34012 327844 12935 0.176 101.0045 Find By Formula Cpd 1: C17 H18 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H18 O3 98.42 -2.66 (M+H)+ (M+Na)+ 271.1339 293.1154
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
293.1154 (M+Na)+ 98.42 97.39 99.3 99.44 13063.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
293.1154 293.1148 -1.96 12934.8 13063.4 100 100 82.7 81.8
294.119 294.1182 -2.8 2493.8 2443.9 19.3 18.7 15.5 15.8
295.1206 295.1209 0.99 374.9 296.1 2.9 2.3 1.9 2.4
271.1339 (M+H)+ 61 89.31 19.91 53.68 3607.1
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
271.1339 271.1329 -3.95 3607.1 3509.5 100 100 82.7 85
272.1412 272.1363 -18.16 325.7 657 9 18.7 15.5 7.7
273.1375 273.139 5.22 313.2 79.6 8.7 2.3 1.9 7.4
C15 H14 O3 TRUE 1 3 FBF FBF 95.02 0.25 0.388 0.573 265.0823 242.0932 242.0943 95.02 -4.65 -1.13 Positive 7 1 1 1 27985 239428 13591 0.18 101.0041 Find By Formula Cpd 1: C15 H14 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C15 H14 O3 95.02 4.65 (M+H)+ (M+NH4)+ (M+Na)+ 243.1003 260.1292 265.0823
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
265.0823 (M+Na)+ 95.02 90.07 99.55 99.49 13713.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
265.0823 265.0835 4.44 13591.2 13713.6 100 100 84.4 83.6
266.0859 266.0869 3.59 2317.1 2262.6 17 16.5 13.9 14.3
267.0894 267.0895 0.43 319.2 259.2 2.3 1.9 1.6 2
268.0896 268.0921 9.52 30.2 22.3 0.2 0.2 0.1 0.2
243.1003 (M+H)+ 74.61 87.69 74.32 48.79 2042.3
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
243.1003 243.1016 5.31 1958.2 2042.3 100 100 85.8 82.3
244.1041 244.105 3.6 421.3 337.2 21.5 16.5 14.2 17.7
260.1292 (M+NH4)+ 43.14 90.58 0 0 110.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
260.1292 260.1281 -4.18 110.7 110.7 100 100 100 100
C14 H14 O5 TRUE 1 4 FBF FBF 90.37 0.243 0.267 0.315 285.0719 262.0826 262.0841 90.37 -5.86 -1.53 Positive 5 1 1 1 17061 37604 7230 0.046 434.3132 Find By Formula Cpd 1: C14 H14 O5 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C14 H14 O5 90.37 5.86 (M+H)+ (M+Na)+ 263.0900 285.0719
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
285.0719 (M+Na)+ 90.37 82.94 98.64 95.29 7328.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
285.0719 285.0733 5.11 7229.6 7328.5 100 100 85 83.9
286.0744 286.0767 8.13 1198.1 1135.4 16.6 15.5 13.2 13.9
287.0785 287.0789 1.58 193.5 157.3 2.7 2.1 1.8 2.2
263.09 (M+H)+ 76.05 83.34 87.98 47.17 2967.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
263.09 263.0914 5.26 2908.7 2967.7 100 100 86.6 84.9
264.0928 264.0948 7.73 519.2 460.1 17.8 15.5 13.4 15.1
C17 H18 O3 No H adduct TRUE 1 5 FBF FBF 95.91 0.258 0.276 0.338 293.1151 270.1259 270.1256 95.91 1.03 0.28 Positive 4 1 1 1 14526 36439 6063 0.054 434.3157 Find By Formula Cpd 1: C17 H18 O3 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H18 O3 95.91 -1.03 (M+NH4)+ (M+Na)+ 288.1680 293.1151
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
293.1151 (M+Na)+ 95.91 99.65 87.05 99.08 6111.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
293.1151 293.1148 -1.02 6062.8 6111.9 100 100 82.7 82
294.1182 294.1182 -0.08 1310.6 1143.4 21.6 18.7 15.5 17.7
295.109 295.1209 40.44 20.4 138.6 0.3 2.3 1.9 0.3
288.168 (M+NH4)+ 0.17 0.35 0 0 54.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
288.168 288.1594 -29.83 54.6 54.6 100 100 100 100
C16 H16 O3 TRUE 1 6 FBF FBF 93.51 0.258 0.277 0.33 279.0979 256.1082 256.1099 93.51 -6.75 -1.73 Positive 7 1 1 1 41588 82810 12440 0.024 434.3123 Find By Formula Cpd 1: C16 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C16 H16 O3 93.51 6.75 (M+H)+ (M+Na)+ 257.1156 279.0979
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
279.0979 (M+Na)+ 93.51 87.34 99.58 98.57 12440.1
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
279.0979 279.0992 4.63 12440.1 12366.3 100 100 83.4 83.9
280.1015 280.1026 3.8 2144.8 2176.9 17.2 17.6 14.7 14.5
281.0999 281.1052 18.8 194.6 256.3 1.6 2.1 1.7 1.3
282.1065 282.1078 4.62 42.6 22.7 0.3 0.2 0.2 0.3
257.1156 (M+H)+ 68.86 64.5 83.49 60.03 9458.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
257.1156 257.1172 6.36 9052.1 9458.4 100 100 83.5 80
258.1191 258.1206 5.73 1716.3 1666.1 19 17.6 14.7 15.2
259.108 259.1233 58.95 552.3 196.2 6.1 2.1 1.7 4.9
C16 H16 O3 No H adduct TRUE 1 7 FBF FBF 98 0.309 0.39 0.587 279.0993 256.1102 256.1099 98 0.89 0.23 Positive 3 1 1 1 45618 308073 9520 0.101 101.0041 Find By Formula Cpd 1: C16 H16 O3 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C16 H16 O3 98 -0.89 (M+Na)+ 279.0993
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
279.0993 (M+Na)+ 98 99.59 95.3 98.07 9519.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
279.0993 279.0992 -0.47 9519.9 9375.8 100 100 83.6 84.8
280.1031 280.1026 -2.09 1468.3 1650.5 15.4 17.6 14.7 13.1
281.1072 281.1052 -7.27 232.5 194.3 2.4 2.1 1.7 2.1
C16 H16 O3 TRUE 1 7 FBF FBF 97.98 0.315 0.334 0.401 257.1166 256.1091 256.1099 97.98 -3.14 -0.8 Positive 8 1 1 1 790148 1376614 66976 0.026 434.312 Find By Formula Cpd 1: C16 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C16 H16 O3 97.98 3.14 (M+H)+ (M+NH4)+ (M+Na)+ 257.1166 274.1401 279.0981
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
257.1166 (M+H)+ 97.98 96.36 99.31 99.62 66975.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
257.1166 257.1172 2.4 66975.8 66449.2 100 100 83.4 84.1
258.1198 258.1206 3.28 11237.8 11705 16.8 17.6 14.7 14.1
259.1231 259.1233 0.57 1231.5 1378.4 1.8 2.1 1.7 1.5
260.1178 260.1259 31.08 209.5 122 0.3 0.2 0.2 0.3
279.0981 (M+Na)+ 94.83 90.52 98.83 98.64 28966.3
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
279.0981 279.0992 3.74 28966.3 28803.5 100 100 83.6 84
280.1013 280.1026 4.48 4806.8 5070.4 16.6 17.6 14.7 13.9
281.1016 281.1052 12.8 697.7 596.9 2.4 2.1 1.7 2
274.1401 (M+NH4)+ 16.44 34.52 0 0 105.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
274.1401 274.1438 13.3 105.7 105.7 100 100 100 100
C17 H16 O3 No H adduct TRUE 1 8 FBF FBF 97.78 0.332 0.409 0.611 291.0986 268.1093 268.1099 97.78 -2.23 -0.6 Positive 3 1 1 1 21333 175801 5860 0.126 101.0037 Find By Formula Cpd 1: C17 H16 O3 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H16 O3 97.78 2.23 (M+Na)+ 291.0986
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
291.0986 (M+Na)+ 97.78 97.33 97.1 99.49 5859.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
291.0986 291.0992 1.91 5859.6 5756.9 100 100 82.7 84.2
292.102 292.1026 2.02 1061.1 1075.7 18.1 18.7 15.4 15.2
293.0987 293.1053 22.33 42.1 130.3 0.7 2.3 1.9 0.6
C17 H12 O3 TRUE 1 9 FBF FBF 99.23 0.244 0.277 0.325 287.0679 264.0783 264.0786 99.23 -1.36 -0.36 Positive 5 1 1 1 23302 38010 7700 0.018 255.0043 Find By Formula Cpd 1: C17 H12 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H12 O3 99.23 1.36 (M+H)+ (M+Na)+ 265.0842 287.0679
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
287.0679 (M+Na)+ 99.23 99.99 99.27 97.66 7700
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
287.0679 287.0679 0.03 7700 7696.9 100 100 82.7 82.8
288.0708 288.0712 1.7 1391.3 1434.6 18.1 18.6 15.4 15
289.076 289.0739 -7.17 213.8 173.5 2.8 2.3 1.9 2.3
265.0842 (M+H)+ 72.31 84.26 85.51 32.58 2350
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
265.0842 265.0859 6.67 2293.9 2350 100 100 84.3 82.3
266.0894 266.0893 -0.28 494.5 438.3 21.6 18.7 15.7 17.7
C17 H16 O3 TRUE 1 10 FBF FBF 97.91 0.259 0.279 0.322 291.0998 268.1089 268.1099 97.91 -3.72 -1 Positive 6 1 1 1 40449 72050 14499 0.022 255.0052 Find By Formula Cpd 1: C17 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H16 O3 97.91 3.72 (M+H)+ (M+Na)+ 269.1178 291.0998
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
291.0998 (M+Na)+ 97.91 97.22 98.42 98.68 14499.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
291.0998 291.0992 -2.11 14499.2 14316.2 100 100 82.7 83.7
292.1034 292.1026 -3.05 2652.7 2675 18.3 18.7 15.4 15.3
293.1009 293.1053 14.86 163.1 323.9 1.1 2.3 1.9 0.9
269.1178 (M+H)+ 33.44 40.39 0 59.68 9821.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
269.1178 269.1172 -2.08 7322.9 9821.8 100 100 82.7 61.6
270.121 270.1206 -1.26 1423.3 1836.3 19.4 18.7 15.5 12
271.1092 271.1233 52.09 3134.4 222.4 42.8 2.3 1.9 26.4
C16 H14 O3 TRUE 1 11 FBF FBF 98.74 0.356 0.443 0.611 277.0838 254.0947 254.0943 98.74 1.53 0.39 Positive 6 1 1 1 250451 2286733 4234 0.151 157.0355 Find By Formula Cpd 1: C16 H14 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C16 H14 O3 98.74 -1.53 (M+H)+ (M+Na)+ 255.1021 277.0838
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
277.0838 (M+Na)+ 98.74 98.81 99.27 97.94 4250
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
277.0838 277.0835 -1.19 4233.8 4250 100 100 83.6 83.3
278.0871 278.0869 -0.85 734.1 747.2 17.3 17.6 14.7 14.4
279.0929 279.0895 -12.13 117.2 87.9 2.8 2.1 1.7 2.3
255.1021 (M+H)+ 96.9 98.73 95.37 95.07 28736.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
255.1021 255.1016 -2.07 28736.9 28209.6 100 100 83.6 85.1
256.1046 256.105 1.3 4984.1 4962.6 17.3 17.6 14.7 14.8
257.0949 257.1076 49.2 35.3 584 0.1 2.1 1.7 0.1
S32
C20 H16 O3 TRUE 1 12 FBF FBF 98.09 0.251 0.275 0.313 327.0987 304.1094 304.1099 98.09 -1.95 -0.59 Positive 7 1 1 1 75065 129456 34133 0.025 255.0034 Find By Formula Cpd 1: C20 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C20 H16 O3 98.09 1.95 (M+H)+ (M+Na)+ 305.1166 327.0987
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
327.0987 (M+Na)+ 98.09 97.59 98.62 98.44 34244.1
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
327.0987 327.0992 1.51 34132.6 34244.1 100 100 79.9 79.7
328.1019 328.1025 1.85 7241.9 7509.6 21.2 21.9 17.5 16.9
329.1026 329.1054 8.39 1182.4 994.5 3.5 2.9 2.3 2.8
330.1044 330.1081 11.38 289.2 97.9 0.8 0.3 0.2 0.7
305.1166 (M+H)+ 97.89 97.64 97.64 98.68 7545.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
305.1166 305.1172 2.04 7524.5 7545.5 100 100 80.1 79.9
306.1204 306.1206 0.62 1589.8 1655.6 21.1 21.9 17.6 16.9
307.1221 307.1235 4.35 306.2 219.3 4.1 2.9 2.3 3.3
C19 H14 O3 TRUE 1 13 FBF FBF 97.19 0.261 0.28 0.338 291.1012 290.0938 290.0943 97.19 -1.83 -0.53 Positive 3 1 1 1 14634 13099 4740 0.011 313.267 Find By Formula Cpd 1: C19 H14 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C19 H14 O3 97.19 1.83 (M+H)+ 291.1012
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
291.1012 (M+H)+ 97.19 97.89 95.97 97.26 4739.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
291.1012 291.1016 1.35 4739.6 4661.9 100 100 81 82.3
292.1041 292.105 2.84 980 971.4 20.7 20.8 16.9 17
293.098 293.1078 33.42 38.4 124.8 0.8 2.7 2.2 0.7
C19 H14 O3 TRUE 1 14 FBF FBF 97.78 0.262 0.274 0.327 291.1017 290.0947 290.0943 97.78 1.24 0.36 Positive 3 1 1 1 23394 30693 4858 0.016 313.2579 Find By Formula Cpd 1: C19 H14 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C19 H14 O3 97.78 -1.24 (M+H)+ 291.1017
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
291.1017 (M+H)+ 97.78 99.02 98.55 94.37 4865.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
291.1017 291.1016 -0.61 4858.4 4865.5 100 100 81 80.8
292.1056 292.105 -2.33 979.2 1013.8 20.2 20.8 16.9 16.3
293.1115 293.1078 -12.67 171.8 130.2 3.5 2.7 2.2 2.9
C22 H25 N O4 TRUE 1 15 FBF FBF 98.96 0.265 0.281 0.53 368.1858 367.1786 367.1784 98.96 0.77 0.28 Positive 7 1 1 1 131984 1058164 73464 0.17 426.2405 Find By Formula Cpd 1: C22 H25 N O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C22 H25 N O4 98.96 -0.77 (M+H)+ (M+Na)+ 368.1858 390.1681
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
368.1858 (M+H)+ 98.96 99.91 96.55 99.93 73464.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
368.1858 368.1856 -0.37 73464.5 72097.7 100 100 77.7 79.1
369.1891 369.1889 -0.46 16437 17744.2 22.4 24.6 19.1 17.7
370.1914 370.1917 0.93 2606.1 2682.9 3.5 3.7 2.9 2.8
371.192 371.1944 6.57 319.7 302.5 0.4 0.4 0.3 0.3
390.1681 (M+Na)+ 98.75 98.66 97.88 99.97 59497.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
390.1681 390.1676 -1.22 59497.8 58652.6 100 100 77.9 79.1
391.1714 391.1709 -1.2 13593.3 14428.4 22.8 24.6 19.2 18.1
392.1745 392.1737 -2.04 2170.9 2180.9 3.6 3.7 2.9 2.9
C24 H23 N O4 TRUE 1 16 FBF FBF 96.5 0.254 0.278 0.302 390.1711 389.1643 389.1627 96.5 4.06 1.58 Positive 8 1 1 1 136739 214067 44899 0.028 448.2274 Find By Formula Cpd 1: C24 H23 N O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C24 H23 N O4 96.5 -4.06 (M+H)+ (M+Na)+ 390.1711 412.1539
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
390.1711 (M+H)+ 96.5 94.59 99.19 97.08 44899.1
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
390.1711 390.17 -2.9 44899.1 44345.7 100 100 76 77
391.1736 391.1733 -0.87 11486.9 11863.1 25.6 26.8 20.3 19.7
392.1779 392.1761 -4.38 1830.4 1888.7 4.1 4.3 3.2 3.1
393.1767 393.1789 5.48 103.8 222.6 0.2 0.5 0.4 0.2
412.1539 (M+Na)+ 88.69 78.64 97.81 97.83 50658
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
412.1539 412.1519 -4.78 50658 49631.5 100 100 76 77.6
413.1575 413.1552 -5.58 12604 13271.4 24.9 26.7 20.3 19.3
414.1627 414.1581 -11.04 1816.4 2112.3 3.6 4.3 3.2 2.8
415.1649 415.1608 -9.81 185.7 248.9 0.4 0.5 0.4 0.3
C14 H14 O4 TRUE 1 17 FBF FBF 87.57 0.246 0.265 0.313 269.0769 246.0882 246.0892 87.57 -4.14 -1.02 Positive 6 1 1 1 9806 21115 4399 0.029 434.3124 Find By Formula Cpd 1: C14 H14 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C14 H14 O4 87.57 4.14 (M+H)+ (M+Na)+ 247.0973 269.0769
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
269.0769 (M+Na)+ 87.57 79.95 98.51 89.66 4399.3
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
269.0769 269.0784 5.71 4399.3 4382.8 100 100 85.2 85.5
270.079 270.0818 10.38 700.8 677.4 15.9 15.5 13.2 13.6
271.0883 271.0841 -15.31 44.9 84.8 1 1.9 1.6 0.9
247.0973 (M+H)+ 64.94 92.19 3.31 84.39 1410.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
247.0973 247.0965 -3.12 1174 1410.9 100 100 85.2 70.9
248.1018 248.0999 -7.7 447.1 218.2 38.1 15.5 13.2 27
249.0977 249.1022 18.23 35.3 27.3 3 1.9 1.6 2.1
C13 H12 O4 TRUE 1 18 FBF FBF 99.79 0.298 0.322 0.38 233.0808 232.0734 232.0736 99.79 -0.7 -0.16 Positive 7 1 1 1 104896 115752 40323 0.015 434.3136 Find By Formula Cpd 1: C13 H12 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H12 O4 99.79 0.7 (M+H)+ (M+Na)+ 233.0808 255.0603
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
233.0808 (M+H)+ 99.79 99.98 99.54 99.71 40322.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
233.0808 233.0808 0.09 40322.7 40265.3 100 100 86 86.1
234.084 234.0842 0.93 5588.9 5783 13.9 14.4 12.3 11.9
235.0862 235.0865 1.14 853.4 715.6 2.1 1.8 1.5 1.8
236.0892 236.0891 -0.21 62.2 63.1 0.2 0.2 0.1 0.1
255.0603 (M+Na)+ 74.9 67.56 92.23 68.78 2347.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
255.0603 255.0628 9.58 2347.6 2276.3 100 100 86.1 88.8
256.0667 256.0662 -1.99 272.7 326.7 11.6 14.4 12.4 10.3
257.065 257.0684 13.06 23.1 40.4 1 1.8 1.5 0.9
C13 H12 O4 TRUE 1 19 FBF FBF 99.23 0.411 0.483 0.598 233.0811 232.0739 232.0736 99.23 1.29 0.3 Positive 4 1 1 1 35548 228264 16226 0.116 157.0355 Find By Formula Cpd 1: C13 H12 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H12 O4 99.23 -1.29 (M+H)+ 233.0811
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
233.0811 (M+H)+ 99.23 99.19 99.82 98.59 16309.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
233.0811 233.0808 -1.05 16225.9 16309.4 100 100 86 85.5
234.0849 234.0842 -2.92 2355.4 2342.4 14.5 14.4 12.3 12.4
235.0866 235.0865 -0.81 347.8 289.9 2.1 1.8 1.5 1.8
236.0892 236.0891 -0.4 38.2 25.6 0.2 0.2 0.1 0.2
C12 H11 N O4 low score TRUE 1 20 FBF FBF 81.16 0.252 0.286 0.329 234.0764 233.0668 233.0688 81.16 -8.77 -2.04 Positive 6 1 1 1 28942 92583 1901 0.074 255.0051 Find By Formula Cpd 1: C12 H11 N O4 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C12 H11 N O4 81.16 8.77 (M+H)+ (M+Na)+ 234.0764 256.0574
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
234.0764 (M+H)+ 81.16 98.49 83.56 43.62 1901.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
234.0764 234.0761 -1.37 1901.5 1838.8 100 100 88 91
235.0806 235.0793 -5.52 188 250.7 9.9 13.6 12 9
256.0574 (M+Na)+ 42.26 65.69 18.44 23.97 24500.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
256.0574 256.058 2.28 21042.3 24500.6 100 100 86.6 74.4
257.0549 257.0613 24.69 5989 3337.7 28.5 13.6 11.8 21.2
258.0529 258.0634 40.75 1169.3 411.4 5.6 1.7 1.5 4.1
259.0615 259.066 17.47 84.6 35.4 0.4 0.1 0.1 0.3
C11 H10 O3 TRUE 1 21 FBF FBF 99.23 0.25 0.375 0.61 213.0522 190.0629 190.063 99.23 -0.67 -0.13 Positive 4 1 1 1 13751 107460 5882 0.135 101.0043 Find By Formula Cpd 1: C11 H10 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C11 H10 O3 99.23 0.67 (M+H)+ (M+Na)+ 191.0701 213.0522
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
213.0522 (M+Na)+ 99.23 99.85 99.55 97.61 5882.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
213.0522 213.0522 0.14 5882.2 5876.4 100 100 88.2 88.3
214.0552 214.0556 2.07 732.6 712.6 12.5 12.1 10.7 11
215.0513 215.0578 30.03 49.9 75.7 0.8 1.3 1.1 0.7
191.0701 (M+H)+ 47.39 99.53 0 0 314.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
191.0701 191.0703 1.1 314.4 314.4 100 100 100 100
C13 H12 O5 TRUE 1 22 FBF FBF 92.92 0.249 0.311 0.585 271.0571 248.0679 248.0685 92.92 -2.18 -0.54 Positive 6 1 1 1 20028 141679 2539 0.101 101.0039 Find By Formula Cpd 1: C13 H12 O5 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H12 O5 92.92 2.18 (M+H)+ (M+Na)+ 249.0754 271.0571
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
271.0571 (M+Na)+ 92.92 97.1 86.4 92.36 2618
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
271.0571 271.0577 2.23 2538.8 2618 100 100 85.9 83.3
272.0612 272.0611 -0.37 463.1 376.7 18.2 14.4 12.4 15.2
273.0553 273.0632 28.67 44.9 52 1.8 2 1.7 1.5
249.0754 (M+H)+ 87.21 97.8 69.9 86.82 4792.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
249.0754 249.0757 1.45 4792.9 4597.7 100 100 85.9 89.6
250.0771 250.0791 8.21 424.8 662.1 8.9 14.4 12.4 7.9
251.0804 251.0812 3.11 133.5 91.4 2.8 2 1.7 2.5
C15 H14 O3 TRUE 1 23 FBF FBF 96.86 0.254 0.28 0.323 265.0833 242.0939 242.0943 96.86 -1.73 -0.42 Positive 6 1 1 1 17303 34114 7727 0.037 434.3145 Find By Formula Cpd 1: C15 H14 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C15 H14 O3 96.86 1.73 (M+H)+ (M+NH4)+ (M+Na)+ 243.1009 260.1268 265.0833
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
265.0833 (M+Na)+ 96.86 99.23 94.45 95.01 7929.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
265.0833 265.0835 0.73 7727.3 7929.6 100 100 84.5 82.3
266.0858 266.0869 3.99 1469 1308.3 19 16.5 13.9 15.6
267.0904 267.0895 -3.36 191.5 149.9 2.5 1.9 1.6 2
243.1009 (M+H)+ 84.14 95.07 95.27 48.92 2348.3
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
243.1009 243.1016 2.88 2343.2 2348.3 100 100 85.8 85.6
244.1039 244.105 4.46 392.8 387.7 16.8 16.5 14.2 14.4
260.1268 (M+NH4)+ 41.32 86.76 0 0 138.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
260.1268 260.1281 5.01 138.2 138.2 100 100 100 100
C11 H6 O3 TRUE 1 24 FBF FBF 88.65 0.249 0.287 0.354 187.0391 186.0315 186.0317 88.65 -1.08 -0.2 Positive 5 1 1 1 16507 38457 6362 0.039 434.3133 Find By Formula Cpd 1: C11 H6 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C11 H6 O3 88.65 1.08 (M+H)+ (M+Na)+ 187.0391 209.0208
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
187.0391 (M+H)+ 88.65 99.63 86.82 68.91 6546.1
S33
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
187.0391 187.039 -0.69 6362.1 6546.1 100 100 88.2 85.7
188.0427 188.0424 -1.59 767.7 791.6 12.1 12.1 10.7 10.3
189.0362 189.0445 44.12 291.8 84 4.6 1.3 1.1 3.9
209.0208 (M+Na)+ 85.51 99.42 96.39 44.62 2483.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
209.0208 209.0209 0.69 2462.4 2483.8 100 100 89.2 88.5
210.0233 210.0243 4.7 321.4 300.1 13.1 12.1 10.8 11.5
C15 H12 O4 TRUE 1 25 FBF FBF 98.94 0.251 0.278 0.389 257.0805 256.0731 256.0736 98.94 -1.6 -0.41 Positive 6 1 1 1 32512 89149 15550 0.035 434.3128 Find By Formula Cpd 1: C15 H12 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C15 H12 O4 98.94 1.6 (M+H)+ (M+Na)+ 257.0805 279.0618
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
257.0805 (M+H)+ 98.94 98.86 98.32 99.83 15762.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
257.0805 257.0808 1.32 15550.5 15762.2 100 100 84.3 83.2
258.0837 258.0842 1.9 2775.9 2604.8 17.9 16.5 13.9 14.8
259.086 259.0866 2.36 371.6 331 2.4 2.1 1.8 2
279.0618 (M+Na)+ 80.34 93.4 78.66 56.25 1289.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
279.0618 279.0628 3.34 1211.7 1289.9 100 100 84.3 79.2
280.0671 280.0662 -3.46 246.1 213 20.3 16.5 13.9 16.1
281.0612 281.0686 26.33 72.1 27.1 6 2.1 1.8 4.7
C13 H10 O4 low score TRUE 1 26 FBF FBF 81.33 0.251 0.275 0.327 231.0661 230.0594 230.0579 81.33 6.64 1.53 Positive 3 1 1 1 7301 13683 571 0.035 434.3144 Find By Formula Cpd 1: C13 H10 O4 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H10 O4 81.33 -6.64 (M+H)+ (M+NH4)+ 231.0661 248.0970
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
231.0661 (M+H)+ 81.33 93.82 93.53 41.7 571.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
231.0661 231.0652 -4.14 571.4 562.5 100 100 87.5 88.8
232.0684 232.0686 0.67 71.7 80.7 12.6 14.3 12.5 11.2
248.097 (M+NH4)+ 4.38 9.2 0 0 120.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
248.097 248.0917 -21.1 120.9 120.9 100 100 100 100
C13 H10 O4 TRUE 1 26 FBF FBF 96.62 0.246 0.275 0.385 231.0645 230.0563 230.0579 96.62 -7.13 -1.64 Positive 6 1 1 1 61616 162701 20584 0.037 434.312 Find By Formula Cpd 1: C13 H10 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H10 O4 96.62 7.13 (M+H)+ (M+Na)+ 231.0645 253.0426
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
231.0645 (M+H)+ 96.62 95.18 96.49 99.68 20583.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
231.0645 231.0652 3.11 20583.8 20397.2 100 100 86.1 86.9
232.0677 232.0686 3.91 3047.8 2924.8 14.8 14.3 12.3 12.9
233.0752 233.0708 -19.07 52.3 361.8 0.3 1.8 1.5 0.2
253.0426 (M+Na)+ 57.86 16.33 96.6 94.45 6257.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
253.0426 253.0471 18.01 6197.7 6257.4 100 100 86.1 85.3
254.0452 254.0505 20.96 990.4 896.5 16 14.3 12.3 13.6
255.0541 255.0527 -5.5 76.8 110.9 1.2 1.8 1.5 1.1
C13 H12 O3 TRUE 1 27 FBF FBF 97.24 0.258 0.393 0.541 239.0678 216.0786 216.0786 97.24 -0.04 -0.01 Positive 5 1 1 1 15276 101342 7246 0.155 101.0042 Find By Formula Cpd 1: C13 H12 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H12 O3 97.24 0.04 (M+H)+ (M+Na)+ 217.0897 239.0678
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
239.0678 (M+Na)+ 97.24 99.85 92.59 97.61 7473
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
239.0678 239.0679 0.12 7245.6 7473 100 100 86.3 83.7
240.0709 240.0713 1.42 1126.9 1069.6 15.6 14.3 12.4 13
241.0718 241.0737 7.74 286.9 116.9 4 1.6 1.4 3.3
217.0897 (M+H)+ 38.38 33.24 60.85 21.7 273.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
217.0897 217.0859 -17.55 258.2 273.6 100 100 87.5 82.5
218.0906 218.0893 -6.03 54.7 39.2 21.2 14.3 12.5 17.5
C15 H16 O3 TRUE 1 28 FBF FBF 86.01 0.258 0.275 0.328 267.0989 244.1098 244.1099 86.01 -0.52 -0.13 Positive 4 1 1 1 15166 36899 8252 0.049 434.315 Find By Formula Cpd 1: C15 H16 O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C15 H16 O3 86.01 0.52 (M+H)+ (M+Na)+ 245.1179 267.0989
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
267.0989 (M+Na)+ 86.01 99.72 94.3 48.66 8313.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
267.0989 267.0992 0.95 8251.6 8313.4 100 100 85.8 85.2
268.1028 268.1026 -0.74 1435.3 1373.5 17.4 16.5 14.2 14.8
245.1179 (M+H)+ 78 99.68 94.5 14.86 1563.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
245.1179 245.1172 -2.85 1553 1563.2 100 100 85.8 85.3
246.1179 246.1206 11.09 268.7 258.4 17.3 16.5 14.2 14.7
C18 H14 O4 low score; No H adduct TRUE 1 29 FBF FBF 42.63 0.294 0.414 0.5 317.0754 294.0863 294.0892 42.63 -9.96 -2.93 Positive 2 1 1 1 17305 122866 9252 0.126 101.0036 Find By Formula Cpd 1: C18 H14 O4 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C18 H14 O4 42.63 9.96 (M+Na)+ 317.0754
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
317.0754 (M+Na)+ 42.63 54.75 21.46 43.8 9252.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
317.0754 317.0784 9.56 9252.4 8315.6 100 100 83.5 92.9
318.0802 318.0818 5.07 708.1 1645 7.7 19.8 16.5 7.1
C12 H9 N O3 TRUE 1 30 FBF FBF 96.92 0.249 0.278 0.389 216.0653 215.0579 215.0582 96.92 -1.59 -0.34 Positive 5 1 1 1 23225 58730 8981 0.035 434.3125 Find By Formula Cpd 1: C12 H9 N O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C12 H9 N O3 96.92 1.59 (M+H)+ (M+Na)+ 216.0653 238.0464
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
216.0653 (M+H)+ 96.92 99.59 91.11 98.56 8980.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
216.0653 216.0655 1.18 8980.5 8744 100 100 86.9 89.3
217.0689 217.0687 -0.79 955.7 1186.9 10.6 13.6 11.8 9.5
218.0714 218.071 -1.81 122.9 128.3 1.4 1.5 1.3 1.2
238.0464 (M+Na)+ 77.36 90.21 78.98 49.71 1656
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
238.0464 238.0475 4.62 1594.7 1656 100 100 88.1 84.8
239.0498 239.0507 3.78 285.9 224.6 17.9 13.6 11.9 15.2
C18 H15 N O4 TRUE 1 31 FBF FBF 90.74 0.281 0.347 0.573 310.1081 309.1003 309.1001 90.74 0.63 0.19 Positive 3 1 1 1 5825 30902 1600 0.076 101.0039 Find By Formula Cpd 1: C18 H15 N O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C18 H15 N O4 90.74 -0.63 (M+H)+ 310.1081
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
310.1081 (M+H)+ 90.74 99.73 89.24 74.54 1635.4
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
310.1081 310.1074 -2.24 1600.5 1635.4 100 100 81.4 79.6
311.1097 311.1107 3.11 378 329.9 23.6 20.2 16.4 18.8
312.102 312.1132 36.03 31.7 45 2 2.8 2.2 1.6
C14 H17 N O2 TRUE 1 32 FBF FBF 94.32 0.251 0.271 0.3 232.1321 231.1248 231.1259 94.32 -4.9 -1.13 Positive 3 1 1 1 74295 113147 16614 0.025 255.0041 Find By Formula Cpd 1: C14 H17 N O2 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C14 H17 N O2 94.32 4.9 (M+H)+ 232.1321
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
232.1321 (M+H)+ 94.32 88.88 99.12 99.45 16788
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
232.1321 232.1332 4.98 16614.5 16788 100 100 85.2 84.3
233.1356 233.1365 3.88 2777.2 2650.9 16.7 15.8 13.5 14.1
234.1371 234.1391 8.52 311.6 264.4 1.9 1.6 1.3 1.6
C17 H14 O4 TRUE 1 33 FBF FBF 94.23 0.224 0.253 0.306 305.0782 282.0887 282.0892 94.23 -1.89 -0.53 Positive 6 1 1 1 8545 18538 3146 0.03 434.3168 Find By Formula Cpd 1: C17 H14 O4 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C17 H14 O4 94.23 1.89 (M+H)+ (M+Na)+ 283.0967 305.0782
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
305.0782 (M+Na)+ 94.23 99.01 85.17 95.56 3294.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
305.0782 305.0784 0.87 3146.1 3294.7 100 100 82.5 78.8
306.0816 306.0818 0.85 650.8 616.1 20.7 18.7 15.4 16.3
307.0819 307.0844 7.87 195.4 81.4 6.2 2.5 2 4.9
283.0967 (M+H)+ 61.14 92.63 15.47 52.99 1169.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
283.0967 283.0965 -0.76 1012.7 1169.5 100 100 82.5 71.5
284.099 284.0999 3.2 231.1 218.8 22.8 18.7 15.4 16.3
285.0943 285.1024 28.61 173.5 28.9 17.1 2.5 2 12.2
C18 H16 O5 S TRUE 1 34 FBF FBF 93.84 0.224 0.253 0.306 367.0597 344.0704 344.0718 93.84 -4.18 -1.44 Positive 8 1 1 1 49465 120319 21495 0.038 255.0041 Find By Formula Cpd 1: C18 H16 O5 S Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C18 H16 O5 S 93.84 4.18 (M+H)+ (M+NH4)+ (M+Na)+ 345.0783 362.0975 367.0597
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
367.0597 (M+Na)+ 93.84 87.87 99.87 98.55 21499
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
367.0597 367.0611 3.78 21494.9 21499 100 100 77.3 77.3
368.0629 368.0643 3.82 4393.7 4435.7 20.4 20.6 15.9 15.8
369.0584 369.0609 6.72 1610.8 1617.1 7.5 7.5 5.8 5.8
370.061 370.0628 4.84 315.6 263.2 1.5 1.2 0.9 1.1
345.0783 (M+H)+ 82.93 89.6 80.51 72.49 6437.7
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
345.0783 345.0791 2.34 6067.9 6437.7 100 100 78 73.5
346.0806 346.0824 5.05 1478.1 1329 24.4 20.6 16.1 17.9
347.0743 347.0789 13.37 705.1 484.4 11.6 7.5 5.9 8.5
362.0975 (M+NH4)+ 0.76 1.59 0 0 72.6
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
362.0975 362.1057 22.63 72.6 72.6 100 100 100 100
C13 H12 O5 TRUE 1 35 FBF FBF 99.85 0.234 0.393 0.608 271.0577 248.0684 248.0685 99.85 -0.2 -0.05 Positive 6 1 1 1 23230 286232 10071 0.224 101.0042 Find By Formula Cpd 1: C13 H12 O5 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C13 H12 O5 99.85 0.2 (M+H)+ (M+Na)+ 249.0757 271.0577
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
271.0577 (M+Na)+ 99.85 99.99 99.54 99.94 10131.5
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
271.0577 271.0577 0.16 10071.3 10131.5 100 100 85.9 85.4
272.0611 272.0611 -0.13 1511.8 1457.8 15 14.4 12.4 12.8
273.0628 273.0632 1.49 207.5 201.3 2.1 2 1.7 1.8
249.0757 (M+H)+ 97.84 99.94 93.9 98.35 2889.2
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
249.0757 249.0757 0.25 2826.5 2889.2 100 100 85.9 84.1
250.0793 250.0791 -0.72 478.5 416.1 16.9 14.4 12.4 14.2
251.0781 251.0812 12.51 57.8 57.4 2 2 1.7 1.7
C11 H8 Br N O3 low score; No H adduct TRUE 1 36 FBF FBF 76.16 0.243 0.409 0.55 305.9549 280.9675 280.9688 76.16 -4.35 -1.22 Positive 3 1 1 1 5799 51353 1255 0.189 101.0039 Find By Formula Cpd 1: C11 H8 Br N O3 Warning
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C11 H8 Br N O3 76.16 4.35 (M+Na)+ 305.9549
S34
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
305.9549 (M+Na)+ 76.16 89.68 45.82 85.54 1254.9
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
303.9568 303.958 3.81 1214.6 1241.7 96.8 100 47.4 46.3
304.9583 304.9612 9.48 151.4 154.8 12.1 12.5 5.9 5.8
305.9549 305.956 3.54 1254.9 1224.4 100 98.6 46.7 47.9
C15 H17 N O3 TRUE 1 37 FBF FBF 97.08 0.24 0.264 0.312 260.1285 259.1215 259.1208 97.08 2.56 0.66 Positive 6 1 1 1 32441 68462 6704 0.033 255.0054 Find By Formula Cpd 1: C15 H17 N O3 Pass
Best ID Source Name Formula Score Score (RT) RT Diff Diff (ppm) Score (Lib) Score (DB) Score (MFG) Num Spectra Notes RT (Tgt) RT (DB) Precursor (Acq) Find by MRM Product Ion Species m/z Library
TRUE FBF C15 H17 N O3 97.08 -2.56 (M+H)+ (M+Na)+ 260.1285 282.1110
m/z Species Ion Formula Score (MFG) Score (MFG, MS/MS) Score (MS) Score (mass) Score (iso. abund) Score (iso. spacing) Height
260.1285 (M+H)+ 97.08 98.72 93.31 98.32 6703.8
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
260.1285 260.1281 -1.6 6703.8 6508.2 100 100 84.1 86.7
261.1314 261.1314 0.08 955.1 1100.6 14.2 16.9 14.2 12.3
262.1375 262.1339 -13.64 77.3 127.4 1.2 2 1.6 1
282.111 (M+Na)+ 95.86 94.92 98.98 94.02 11465.3
m/z m/z (Calc) Diff (ppm) Height Height (Calc) Height % Height % (Calc) Height Sum% (Calc) Height Sum %
282.111 282.1101 -3.47 11465.3 11379.8 100 100 84.1 84.8
283.1133 283.1133 -0.01 1820.8 1923 15.9 16.9 14.2 13.5
284.1152 284.1159 2.42 239.3 222.6 2.1 2 1.6 1.8
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Compound 22  2-((2-oxo-2H-chromen-7-yl)oxy)propanoic acid 
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